$GNPX Selects Accenture To Support Acceleration Of Oncoprex Clinical Program

AUSTIN, Texas and CAMBRIDGE, Mass., May 8, 2018 — Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has selected Accenture to provide clinical data management services to help accelerate the clinical development of Genprex’s lead drug candidate, Oncoprex™, for the treatment of non-small cell lung cancer (NSCLC).

“Data traceability is critically important when interacting with the FDA,” said Julien Pham, MD, MPH, President and COO of Genprex. “Rigorous data management is essential, not just in late-stage trials, but throughout the clinical development process.”

Under the agreement, Accenture, a leading global professional services company, is supporting Genprex with clinical data management and submission-compliant CDISC deliverable activities for the Phase I/II clinical trial combining Genprex’s Oncoprex and the EGFR-inhibitor erlotinib (Tarceva®) in stage IV lung cancer.  Accenture’s Clinical Data Management team has executed thousands of clinical trials in a variety of therapeutic areas, supported by experienced industry professionals who understand the importance of a standards-fueled, data-centric approach across each phase of drug development. Clinical data services are a core offering in Accenture’s R&D services business, and the company places a strong emphasis on providing high quality data management using a variety of electronic data capture systems.

“Accenture looks forward to supporting Genprex with the second phase of their Phase I/II clinical trial,” said Thomas Lehmann, managing director, Accenture Accelerated R&D Services. “Our team is committed to bringing our Clinical Data Management services to innovative organizations like Genprex, which are focused on the development of cutting-edge, impactful therapies that promise to improve patient lives.”

About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Visit the company’s web site at www.genprex.com or follow Genprex on Twitter at https://twitter.com/genprex and Facebook at https://www.facebook.com/genprexinc/.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the services we expect to receive from Accenture and the effect of those services on the development of Oncoprex. Risks that contribute to the uncertain nature of the forward-looking statements include Accenture’s ability to provide services to us and our ability to utilize Accenture’s services, the ability of Accenture’s services to influence the development of Oncoprex, as well as the timing and success of our clinical trials and planned clinical trials of Oncoprex and our other potential product candidates and the timing and success of obtaining FDA approval of Oncoprex and our other potential product candidates. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact:

$SEII Enters into a License Agreement with Ecrent Capital Holdings

HONG KONG, May 8, 2018 — Sharing Economy International, Inc. (“SEII” or “the Company”) (NASDAQ: SEII) today announced that its wholly-owned subsidiary, Sharing Economy Investment Limited, has entered into a License Agreement with Ecrent Capital Holdings Limited (“ECRENT”), regarding the grant of an exclusive and sublicensable license from ECRENT to SEII to utilize certain software and trademarks in order to develop, launch, operate, commercialize, and maintain an online website platform in Taiwan, Thailand, India, Indonesia, Singapore, Malaysia, the Philippines, Vietnam, Cambodia, Japan, and Korea. In return, SEII shall issue to ECRENT 530,000 shares of common stock. ECRENT will guarantee that the operation of its related websites, mobile applications and business services will contribute revenue of US$15,000,000 and gross profit of US$2,910,000 from the closing date until December 31, 2019.

“I believe this is the perfect way to start working with ECRENT in pursuit of our common goal of proliferating the sharing economy business,” said Parkson Yip, Vice President of SEII. “We are very happy to have structured this ‘win-win’ cooperative agreement, which enables both of us to utilize the counterparties’ competitive advantages to further develop our own business. Being a leading global rental classified ad platform, ECRENT is becoming the central repository for rental and service opportunities in the global market. ECRENT represents a true sharing model, where people can share and rent items from each other via a peer-to-peer network. ECRENT will play a crucial role in our online strategies to create effective matchups between supply and demand within the SEII sharing economy ecosystem. On one hand, we expect ECRENT will become a revenue driver for SEII; on the other hand, ECRENT will be able to leverage on the technology and marketing expertise, as well as the human resources, of SEII to explore its fruitful overseas markets. We strongly believe that the business operations will create enormous value to our shareholders.”

About Sharing Economy International Inc.

Sharing Economy International Inc., through its affiliated companies, designs, manufactures and distributes a line of proprietary high and low temperature dyeing and finishing machinery to the textile industry. The Company’s latest business initiatives are focused on targeting the technology and global sharing economy markets, by developing online platforms and rental business partnerships that will drive the global development of sharing through economical rental business models. Moreover, the Company will actively pursue blockchain technology in its existing and to-be-acquired business, enabling the general public to realize the beauty of resource sharing. For more information visit www.seii.com

About Ecrent Capital Holdings Limited

ECRENT is one of the largest and most extensive online global sharing platforms which encourages people to share through renting to protect our environment. A number of categories of products and services on wedding, properties, venues, transport, household, tools, equipment, leisure, fashion, accessories, professional services, arts, and public services, can be rented through its platform. For more information visit www.ecrent.com

Safe Harbor Statement

This release contains certain “forward-looking statements” relating to the business of the Company and its subsidiary and affiliated companies and certain potential transactions that they may enter into. These forward looking statements are often identified by the use of forward looking terminology such as “believes,” “expects” or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website, including factors described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K for the year ended December 31, 2017. All forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements.

$AMDA Provides Update on its Clinical Studies

SALT LAKE CITY, May 08, 2018 — Amedica Corporation (NASDAQ: AMDA), an innovative biomaterial company that develops and commercializes silicon nitride for biomedical applications, today provided an update on its clinical study activities.

Single Center Retrospective Comparative Study

A clinical study comparing silicon nitride spinal implants to allograft spacers in cervical fusion showed faster and more effective outcomes with silicon nitride.  “While silicon nitride might have been expected to perform better in light of its properties, the surprising finding in our study was how good the outcomes with silicon nitride proved to be.  Significantly earlier and more effective bone fusion was observed with silicon nitride than allograft spacers at 3- 6-, and 12-month time points after surgery, all the way to 24 months” said Dr. Micah Smith, orthopaedic surgeon in Fort Wayne, Indiana, who is the principal investigator.  Study findings have been submitted to for release at the December 2018 Cervical Spine Research Society meeting.

Multi-Center Retrospective Study

Amedica reported completion of an exhaustive retrospective survey of over 2,000 silicon nitride spinal implants implanted in more than 1,000 patients over the last eight years.  The study was designed to understand clinical outcomes from silicon nitride implants in spine fusion from four different clinics in the US.  “Preliminary data analysis toward publication of this study is very encouraging in this large cohort of patients derived from our long-term surgeon users.  Not only are the data consistent with our other clinical studies, but the outcomes corroborate our basic science understanding of the surface chemistry of the material, the key strength of silicon nitride,” said Dr. Sonny Bal, President of Amedica.

Silicon Nitride Against PEEK (SNAP)

SNAP, a 24-month double-blinded multicenter randomized controlled human trial for lumbar fusion comparing intervertebral cages from either silicon nitride or polyetheretherketone (PEEK), has been completed. The purpose of the study was to show that fusion using silicon nitride cages was at least non-inferior to PEEK devices. Preliminary data at 3, 6, and 12-months on the Roland Morris Disability Questionnaire and VAS back and leg pain scores, as well as quantitative radiographic data at 24 months appear to confirm the study’s hypothesis of silicon nitride’s non-inferiority. Additional detailed analyses are currently being conducted in anticipation of publishing the overall results in a prominent scientific journal later this year.

Goat Study

 An interbody fusion study using a goat model comparing silicon nitride to PEEK was just accepted for publication in the Journal of Biomedical Materials Research, Part B – Applied Biomaterials. The results of the study showed improved fusion and greater bone volume using silicon nitride implants versus PEEK at the study’s six-month end-point. These results also suggest that silicon nitride is not inferior to PEEK and that silicon nitride implants may be more effective in promoting arthrodesis.

About Amedica Corporation
Amedica is focused on the development and application of medical-grade silicon nitride ceramics. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company manufactures its products in its ISO 13485 certified manufacturing facility. Amedica’s spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its OEM partnerships.

For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties. For example, silicon nitride and our products may not have the impact we expect, the outcomes of our ongoing studies may not be positive, and the results of our studies may not come in the anticipated timeframes.   Other factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 29, 2018, and in Amedica’s other filings with the SEC.  Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:
Amedica IR
801-839-3502
IR@amedica.com

$HMMR to Acquire 1stPoint Communications and Its Subsidiaries

POINT PLEASANT BEACH, N.J., May 08, 2018 — via NetworkWire – Hammer Fiber Optics Holdings Corp (OTCQB:HMMR), d/b/a Hammer Communications, announced today that a letter of intent to acquire the stock of 1stPoint Communications, LLC and its subsidiaries, including Open Data Centers, LLC and Endstream Communications, LLC, has been executed by all parties. 1stPoint is a competitive local exchange carrier operating nationwide with intellectual property in services such as SMS/texting, collaboration tools and carrier switching. Endstream Communications offers wholesale voice services worldwide. Open Data Centers operates a carrier-neutral colocation facility in Piscataway, N.J., and will provide the brick-and-mortar capacity to further Hammer’s growth.

“The acquisition is an ideal combination of intellectual property, creates a very strong management team and offers operational synergies for Hammer,” said Erik Levitt, CEO of 1stPoint Communications. “Hammer will not only have the benefit of the exclusive rights to the patented AIR wireless technology but also to 1stPoint’s switching technology, its underlying CLECs and its Commercial Mobile Radio Services operator.”

Hammer Communications operates a fixed wireless network over its own proprietary wireless technology that utilizes DOCSIS 3.0 & DOCSIS 3.1 protocols. Through its access network, Hammer offers Internet, television and voice services to residential customers as well as to small and medium businesses in Atlantic County, N.J. Hammer also offers carrier class services through its fiber-optic network in New York, New Jersey and Pennsylvania. Recently, Hammer Communications has also unveiled its cloud hosting and infrastructure as a service platform offering hosting, cloud and colocation services. As part of the acquisition, the Open Data Centers facility in Piscataway will allow Hammer to expand and grow these offerings.

“We are proud of how far we have been able to take Hammer in the past few quarters,” said Mark Stogdill, founder of Hammer Fiber. “We look forward to how much further these acquisitions will move us in our plans. With the acquisition of 1stPoint’s CLECs and Commercial Mobile Radio Services, we will be able to grow the wireless residential access platform and look toward a national network. In addition, the Open Data Centers facility in Piscataway, along with its server and switching platforms, is a significant addition to our core infrastructure to support major growth in the cloud and hosting markets.”

The details of the transactions and closing dates have not been publicly disclosed.

About Hammer Fiber
Hammer Fiber Optic Holdings Corp. (OTCQB:HMMR) is a telecommunications company investing in the future of wireless technology whose holdings include Hammer Fiber Optic Investments, Ltd. D/B/A Hammer Communications, a New Jersey-based Internet Service Provider (ISP) that offers internet, voice, video and data services in New Jersey, as well as carrier services in Philadelphia and New York. Hammer Fiber serves residential and small business markets with high capacity broadband, voice and video through both direct fiber as well as its wireless fiber platform, Hammer Wireless® AIR technology. For more information visit http://www.hammercomm.com or contact Frank Pena at fpena@hammerfiber.com.

About 1stPoint Communications
1stPoint Communications provides integrated messaging, voice, data and mobile services for small businesses, enterprises and carriers. 1stPoint is committed to delivering all of the services businesses need to interact with their customers, employees and suppliers, providing its clients with A New Way to Work.

About Endstream Communications
Endstream is a wholesale voice operator, providing voice termination, toll origination and toll free origination services to other carrier clients.

About Open Data Centers
Open Data Centers is a carrier neutral colocation facility in Piscataway, NJ. It provides services to 1stPoint Communications, Core Technology Services, Endstream Communications and is a utility data center for over 20 other clients. It is a 2N+1 design with an array of nine fiber providers and 26 resident carriers make it an ideal platform for HMMRs activities.

Forward Looking Statements
This press release contains projections and other forward-looking statements regarding future events or our future financial performance. All statements other than present and historical facts and conditions contained in this release, including any statements regarding our future results of operations and financial positions, business strategy, plans and our objectives for future operations, are forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). These statements are only predictions and reflect our current beliefs and expectations with respect to future events and are based on assumptions and subject to risk and uncertainties and subject to change at any time. We operate in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Actual events or results may differ materially from those contained in the projections or forward-looking statements. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995.

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$BLNK Whole Foods Market Providing Blink Charging #EV Chargers

Whole Foods Market to Join Blink’s Nationwide Charging Station Network

Hollywood, Florida, May 07, 2018 — Leading electric vehicle (EV) charging station owner, operator, and provider Blink Charging Co. (NASDAQ: BLNK, BLNKW) (“Blink Charging” or the “Company”), announced today that it has deployed charging stations at three Whole Foods Markets and are integrated into the development of more stores when they open. The charging stations are an important ingredient to Whole Foods’ continued commitment to sustainability and customer service.

Like all of Blink’s charging stations, the deployed Whole Foods Market units will connect to the Blink Network, a cloud-based system that operates, manages, and tracks the Blink EV charging stations. Any Whole Foods shopper with an electric vehicle will be able to use the charging stations and locate them with use of Blink’s free app.

“Whole Foods Market has always been on the frontlines of innovation in sustainability, and so we are eager to be working with them on their new locations,” said Blink Charging’s CEO Mike Calise. “Whole Foods knows that providing Blink Charging Stations at their stores not only delivers a needed amenity for their EV customers, it also provides the infrastructure for the future of transportation which has already reached a tipping point.”

The new locations with Blink Charging stations are:
•    Lancaster, PA (Fruitville Pike)
•    Spring House, PA (Bethlehem Pike)
•    Exton, PA (N Pottstown Pike)

“Providing Blink Charging services to Whole Foods shoppers is an exciting endeavor because it supports our commitment to making EV charging more accessible,” continued Calise. “Blink is the only charging station provider that is entirely vertically integrated and so with every installation, we’re able to make sure EV drivers will always have a place to charge, no matter where they go.”

About Blink Charging Co.:

Blink Charging (NASDAQ: BLNK, BLNKW) is one of the leaders in nationwide public electric vehicle (EV) charging equipment and services, enabling EV drivers to easily charge at locations throughout the United States. Headquartered in Florida with offices in Arizona and California, Blink Charging’s business is designed to accelerate EV adoption.

Blink Charging offers EV charging equipment and connectivity to the Blink Network, a cloud-based software that operates, manages, and tracks the Blink EV charging stations and all the associated data. Blink Charging also owns and operates EV charging equipment predominantly under the Blink brand, as well as using a number of other charging station equipment manufacturers such as ChargePoint, General Electric (GE) and SemaConnect. Blink Charging has strategic property partners across multiple business sectors including multifamily residential and commercial properties, airports, colleges, municipalities, parking garages, shopping malls, retail parking, schools, and workplaces.

For more information about Blink Charging, please visit BlinkCharging.com

Forward-Looking Statements
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future.  Those statements include statements regarding the intent, belief or current expectations of Blink Charging Co., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

Blink Charging Media Contact:
Stephanie Goldman
Mark Havenner
The Pollack PR Marketing Group
sgoldman@ppmgcorp.com
mhavenner@ppmgcorp.com
(212) 601-9341

$DJACF Canada’s Sizeable Shift From Medical to Recreational Branding

As Canada prepares to make the jump to legalized recreational adult use, the country’s cannabis industry reflects on its branding. Recreational branding is now the hot topic as new partnerships and acquisitions form in the wake of recreational legalization expected to take place this summer.

Narrow audience medical cannabis marketing and recreational cannabis mass audience marketing are vastly different.

Who’s investing in the space? What companies are focused on the Canadian mass market? Here’s the rundown.

One brand to watch is Hiku Brands (CSE:HIKU), newly formed as a result of a merger between Tokyo Smoke, a cannabis retailer of coffee and clothing, and small licensed producer DOJA Cannabis. Furthermore, Hiku just announced a merger with WeedMD (TSX-V: WMD), an effort to join the retail company with the well-known and established producer of medical marijuana in a 51.75 percent Hiku / 48.25 percent WeedMD deal.

Big player Aphria Inc. (TSX:APH) has also been wheeling and dealing. The company recently acquired Broken Coast Cannabis for $230 million.

All of these examples demonstrate just how much money licensed producers are investing in retail brands and companies, many of which are in the early stages of development.

One great example is Choom Holdings Inc. (CSE:CHOO) (OTCQB:CHOOF), which was founded on the premise of developing a brand that would have mass appeal in the Canadian recreational cannabis industry. “Choom” means “smoking marijuana” in Hawaiian. That’s exactly the vibe Choom is going for–the spirit of relaxed good times—straight from the Hawaiian islands to Canadian front doors.

Choom’s exclusive focus is on the recreational cannabis consumer. In fact, they’re one of the very few pure-play recreational public entities. The company has done an impressive job building its vertically integrated, seed-to-sale dedicated recreational cannabis company.

Choom and Emblem Corp. (TSX-V:EMC) just signed a supplier agreement, and Emblem has also acquired an interest in Fire & Flower, a retail cannabis store concept, and lifestyle brand. F&F, valued at approximately $50 million, has applied for 37 retail licenses in Alberta alone and is also exploring retail interests in other Canadian provinces like British Columbia and Saskatchewan.

Choom also owns two British Columbia-based licensed producer applicants, both of which are late-stage applicants. They have agreements in place to acquire two more. With all four poised for approval soon, Choom can ramp up its own production soon. As a plan B, Choom has also entered into a supply agreement with ABcann (TSX-V:ABCN). They’re close partners indeed; in Choom’s recent $7 million raise, ABcann kicked in $4 million.

Choom is casting a wide net when it comes to retail outlets. They’re focusing retail locations and opportunities on the western provinces of Saskatchewan, Alberta, and British Columbia. Currently, Choom has about 50 retail outlets planned there. After that, they’ll focus on moving east. Despite their sizeable investment in the retail brand space, many financial experts say that Choom is undervalued given its market cap of around $60 million.

The market is watching. Their retail outlets should be approved, and any one of its four applicants could be licensed. Time will tell.

$CIIX Enters LOI to Acquire Assets of XBTeller.com

NEW YORK, May 7, 2018 —

ChineseInvestors.com, Inc. (OTCQB: CIIX) (“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, today announces that the Company has entered into a letter of intent (“Letter of Intent”) to acquire the assets of XBTeller.com, a leading Colorado Cryptocurrency ATM and over the counter (“OTC”) operation. The Letter of Intent contemplates: (1) a total investment by the Company of approximately $2,500,000, with $400,000 to be paid in cash and the remainder to be paid in the Company’s restricted stock; (2) an additional investment in the operations of approximately $1,000,000, over the next twelve to eighteen months, that will provide for the expansion of the existing ATM network locations in Colorado and in other states as identified by the Company that will complement the Company’s existing cryptocurrency and blockchain business; and (3) XBTeller.com founders Noah Berger and Alex Syal will join the ChineseInvestors.com, Inc. management team to lead the ATM/OTC operations.  XBTeller.com currently has 9 ATM locations throughout Colorado and is currently reporting approximately $500,000 in unaudited monthly revenues, which includes over the counter transactions.

Chineseinvestors.com, Inc. CFO, Paul Dickman explained “The acquisition of XBTeller.com provides ChineseInvestors.com, Inc. the opportunity to expand its current cryptocurrency and blockchain business to include a retail facing service.”

In 2017, the Company launched Bitcoin Millionaire, a daily cryptocurrency video newscast broadcast from the floor of the NYSE covering all aspects of the emerging digital currency world.  Shortly thereafter, it expanded the coverage of its core internet education services with the launch of http://www.newcoins168.com, a free cryptocurrency and blockchain portal providing up-to-date news and investment education in the Chinese language covering cryptocurrency basics,  trading guidelines, real-time market commentary and analysis covering cryptocurrency, blockchain technology and mining sector related stocks, trends and ETFs, and strategies and opportunities to capitalize on the cryptocurrency market. The Company is also exploring investments into cryptocurrency mining with its recent purchase of ASIC (Application Specific Integrated Circuit) machines used to mine SHA-256 or Scrypt mining algorithms to earn cryptocurrencies such as Bitcoin and Litecoin.

According to Dickman, “The combined synergy of the media and internet education services, the mining, and the ATM/OTC operations is expected to generate $10m-15m in revenue in the first twelve months following complete integration.  The parties have until June 30, 2018 to enter into a definitive asset purchase agreement.  In the furtherance of this objective, the Company has committed to provide a refundable earnest money deposit of $10,000 pending completion of the agreement.”

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products.

For more information visit ChineseInvestors.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom;

https://www.facebook.com/Chineseinvestors.com.english

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776

Investor Relations:
Alan Klitenic
+1-214-636-2548

Corporate Communications:
NetworkNewsWire (NNW)
New York, New York
http://www.NetworkNewsWire.com
212-418-1217 Office
Editor@NetworkNewsWire.com

$CIIX NewCoins168.com Key to Global Leadership on Cryptocurrency, Blockchain

May 7, 2018

• CIIX will offer Bitcoin Trading Academy LLC courses on the website to educate its global Chinese-speaking audience on investing in and buying virtual currency
• NewCoins168.com Digital Media Technology Ltd. is a Shanghai-based, wholly owned foreign enterprise of CIIX designed to expand company’s education programs into China
• CIIX initiates VIP Service on the site at pre-sale price of $888 annually

ChineseInvestors.com, Inc. (OTCQB: CIIX) is increasingly focused on bolstering its leadership role for its global Chinese-speaking audience as producer and educator about global news regarding bitcoin, cryptocurrency, and blockchain technology through its website, NewCoins168.com. It has also launched a paid VIP Service on the site and expanded it into China.

CIIX already has online editorial reporters in New York and Los Angeles and plans to add a total of 10-15 more editors in China at the Shanghai subsidiary to provide 24/7 coverage of the industry, announced Warren Wang, CEO of CIIX (http://nnw.fm/47Qv4). The foreign enterprise, NewCoins168.com Digital Media Technology Ltd. (Shanghai), is located in the China Free Trade Zone.

“The Chinese website is intended to provide entry-level cryptocurrency and blockchain technology information,” Wang said in a news release. “In addition, the company plans to launch a mobile app that will provide timely, 24/7 news and analysis covering cryptocurrency and blockchain technology for the global Chinese community.”

The NewCoins168.com website offers worldwide news of cryptocurrency trading, ICOs, quotes, tutorials and strategies for investing. It also has online registration for paid subscribers to its VIP service, which offers lectures on ICO speculation, long-term trading, options and other subjects.

The company has a comprehensive suite of manufacturing and educational businesses in the cryptocurrency market. It hosts a Bitcoin ATM in the lobby of its San Gabriel, California, headquarters. It also operates a blockchain mining facility with AntMiners and ASIC machines in a secure data center near Seattle, Washington. CIIX broadcasts a daily video from the NYSE titled, ‘Bitcoin MultiMillionaire’, and it has now added VIP Services at $888 annually on its site and expanded it into China. The Bitcoin Trading Academy LLC will offer paid courses on the website.

For more information, visit the company’s website at www.ChineseInvestors.com

More from NetworkNewsWire

• Zenergy Brands, Inc. (ZNGY) Delivers Big Money Savings, Big Environmental Benefits
• Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) Reports 2017 Financial Results Amid Corporate Medical Cannabis Production Successes
• TransCanna Set to Get Marijuana Moving Across California ‘Pot Desert’ Landscape

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$SNNVF 2017 Financial Results Amid Corporate Medical Cannabis Production Successes

May 7, 2018

• Company selected and broke ground on a 126-acre site in Okanagan Falls, British Columbia, to build its planned 700,000 square foot Sunniva Canada Campus
• Company commences extraction production, expected to produce 500 pounds per day of bio mass at California facility
• 489,000-square-foot California facilities to complement its planned 700,000-square-foot facilities in Canada
• Canadian product outlets include supply agreement with Canopy Growth Corp. and patients at acquired Canadian medical cannabis clinics

Rising medical cannabis products and services provider Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) issued a report on April 30 detailing its financial results from fiscal year 2017 (http://cnw.fm/t48SZ). This update arrived on the back of month-long successes, including a bought deal public offering of C$27.8 million, selection of its 126-acre Canadian campus, reception of temporary licensing for the state-of-the-art greenhouse cultivation facilities in Cathedral City, California, and news that President Donald Trump’s administration expects to sustain state-based marijuana legalization efforts in the United States (http://cnw.fm/b6Mfo).

An earnings call on May 1 highlighted that Sunniva began extraction production at the California APL facility in April following the company’s first year of revenue generation through its acquisitions of Canadian medical cannabis clinic network Natural Health Services (NHS), which has more than 95,000 registered active patients, and vaporizer subsidiary Full-Scale Distributors, LLC, which operates as the Vapor Connoisseur brand.

“Our goal is to become a low-cost, high-quality, large-scale producer and manufacturer of medical-grade cannabis products,” Sunniva CEO Anthony Holler said during the conference call. “We intend to accomplish this by building large-scale, purpose-built, Good Manufacturing compliant greenhouse facilities. These facilities will incorporate the latest technologies for environmental control and automation, which will allow us to have consistency in production. … As a management team, we remain committed in our focus on execution to support our business strategy and to deliver shareholder value.”

The California extraction facility is expected to process 500 pounds per day of bio mass for cannabinoid extraction, Holler said, and the company expects related revenue generation to begin in May as it negotiates contracts with a variety of cannabis industry brands for cannabis oil, capsules, sprays, tinctures and creams, as well as custom-made vaporization cartridges. Production of premium cannabis at the Sunniva Campus is expected to increase from a rate of 60,000 kilograms annually to about 100,000 kilograms annually, once phase II is complete.

The California APL extraction facility joins phase I of Sunniva’s in-development 325,000 square foot greenhouse and its planned 700,000 square foot greenhouses slated for its Canada Campus, which is in the final review stage for a license from Health Canada.  The company announced on May 3 that it has selected and broke ground on the 126-acre Okanagan Falls, British Columbia, site to build its Sunniva Canada Campus.  The campus has an overall estimated project budget of approximately C$120 million, which does not include the purchase or lease cost of the land that will underlie the facility (http://cnw.fm/7M5kX).

“In California, we have significant first-mover advantage. We will be the first operational large-scale facility producing pharmaceutical-grade cannabis free of pesticides and other harmful contaminants,” Holler said, adding that current estimates peg some 85 percent of California’s cannabis products with contaminants, including pesticides.

“There is currently very little compliant supply. Obviously, that gives us a significant advantage,” Holler added. “That’s led to discussions with major distributors and major brands in California. … What some of these groups are finding is, they’re getting their product from somewhere; they’re assuming it’s compliant, and then it turns out not to be.”

Holler estimated that the cost of production in California will be below $1 per gram once the facility is fully operation, “as we realize the significant economies of scale, utilizing the energy of the sun and our largely automated climate-controlled facility.”

Sunniva’s wholly owned subsidiary, NHS, has agreements with 27 licensed producers in Canada, and its acquisition of a growing number of NHS clinics provides the company with a steady stream of clients for its cannabinoid products. In addition to its agreement with another licensed producer (LP), Sunniva will produce its own brand for market but plans to remain “agnostic” in terms of brand preference for patients at the clinics, Holler said, noting that the expected number of medical cannabis clients is expected to outpace Sunniva’s own brand production rate.

A significant development in terms of the supply agreement came in February, when Canadian LP Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF) entered into a definitive agreement with Sunniva to purchase, through Sunniva’s wholly-owned subsidiary Sunniva Medical Inc., 45,000 kilograms of premium quality cannabis each year beginning with a two-year period that commences in the first quarter of 2019.

Sunniva’s U.S. subsidiary holds eight 10,000-square-foot cultivation licenses, two manufacturing licenses, one 22,000 square foot cultivation license, one 22,000 square foot nursery license and one 10,000 square foot nursery license. The company will also lease seven 22,000 square foot cultivation bays to its selected licensed tenants (http://cnw.fm/j06zI).

Sunniva began trading publicly on the Canadian Securities Exchange in January and the U.S. OTCQX Market in February. During 2017, the company reported C$16.1 million in revenues, two-thirds of which came from the NHS clinics, according to the April 30 financial report. The company noted an overall net loss of C$18.5 million as it dealt primarily with expenses related to its growth, including the acquisition of NHS and FSD. The company also reported that deferred revenue to help offset those expenses increased to $0.7 million, primarily resulting from customer deposits on sales of merchandise.

For more information, visit the company’s website at www.Sunniva.com

More from CannabisNewsWire

• ChineseInvestors.com’s (CIIX) NewCoins168.com Key to Global Leadership on Cryptocurrency Education, Blockchain Technology News
• TransCanna Set to Get Marijuana Moving Across California ‘Pot Desert’ Landscape
• TransCanna is Out to Control California’s Cannabis Logistics

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$NETE PayOnline Offers Total Payment Facilitator Solution with Bank Sputnik

May 4, 2018

• Net Element specializes in mobile payments and value-added transactional services
• The company supports electronic payments acceptance in a multi-channel environment
• Net Element recently announced that its PayOnline subsidiary is partnering with Bank Sputnik

Payment processor Net Element, Inc. (NASDAQ: NETE) specializes in mobile payments and value-added transactional services. A worldwide technology-driven group, the company provides its platform for small to medium enterprises (SME) in the United States and select developing markets. On Deloitte’s 2017 Technology Fast 500™, Net Element was ranked as one of the fastest growing companies in North America.

The company supports electronic payments acceptance in a multi-channel environment, including point-of-sale, e-commerce and mobile devices. Net Element has positioned itself strategically for growth in emerging countries and the U.S.

Net Element recently announced that its PayOnline subsidiary is partnering with Bank Sputnik to offer a complete multi-channel payment facilitator solution (http://nnw.fm/GFa4E). This solution is for SMB (small and midsize business) merchants in the Russian Federation. Established in 1990, Bank Sputnik is a global bank that provides a comprehensive range of banking services to legal entities and individuals.

Of note is that this payment solution expands PayOnline’s offerings beyond electronic commerce. Moreover, this payment facilitator solution provides a suite of tools not available from any other transaction processing company in the region.

Net Element, by partnering with Bank Sputnik, is at the vanguard of a new operating paradigm in the payment processing industry. Capgemini highlights this paradigm in its report, ‘Top 10 Trends in Payments 2018: What You Need to Know’ (http://nnw.fm/3FbXB). It states, “Banks run the risk of losing market share unless they adapt and change their operating model and become part of the new collaborative payments ecosystem.”

Innovative service offerings, such as the above, should continue to drive growth for Net Element. The company reported 2017 full year revenues of $60.1 million. This represents an increase of roughly 11 percent over its 2016 revenues of $54.3 million. Net Element’s revenue increase in 2017 was significantly driven by its North America Transactions Solutions division.

Net Element’s PayOnline features customizable payment flows. It also features a full-stack Application Programming Interface and value-added solutions. Additionally, PayOnline provisions a single, master merchant identification. As a result, it ensures that merchants and their clients benefit from an automated, real-time and seamless onboarding experience.

In a news release, Andrey Krotov, Net Element’s chief technology officer, stated, “PayOnline exceeds the unique needs of software platforms and merchants looking to enable payments in a multi-channel environment.”

Net Element’s global business strategy is to take advantage of its omni-channel platform. This is to deliver flexible offerings to developing markets with varied banking, regulatory and demographic conditions. In the United States, one way the company is working to grow transactional revenue is through innovating SME productivity services employing blockchain technology solutions.

For more information, visit the company’s website at www.NetElement.com

More from NetworkNewsWire

• Mr. Amazing Loans Corp. (MRAL) – Transition to New Identity in Providing Consumer Loans
• Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) Oil Sands Technology Set to Unlock a Trillion Barrels of Oil Locked in U.S. Sand and Shale
• TransCanna is Out to Control California’s Cannabis Logistics

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$PBIO Enters Agreement Related to Recently Acquired PreEMT™ Platform

Pressure BioSciences, Inc. Announces First Contract Utilizing Recently Acquired High Pressure Technology from BaroFold, Inc.

International Biopharma Client to Evaluate PBI’s Patented PreEMT™ Platform to Enhance Manufacturing Process and Improve Quality of Key Protein Therapeutic Drug Candidate

SOUTH EASTON, MA / May 3, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, high pressure-based instruments and related consumables for the worldwide life sciences industry, today announced that it has signed an agreement with an international biopharmaceutical company to assess the potential of the Company’s recently acquired PreEMT™ platform to develop a unique manufacturing process and improve the quality of a key protein-based drug currently under development.

Protein-based therapeutic drugs are an important part of the global healthcare industry. Based on data in the THPdb database (http://crdd.osdd.net/raghava/thpdb/), there are over 200 therapeutic proteins and peptides approved for clinical use in the US. These drugs have significantly changed therapy options for many diseases, such as cancer and blood disorders. They are the preferred treatment choice for hormone and growth factor deficiencies and are an ideal treatment option for autoimmune disorders. According to a report from Research and Markets (May 2016), the global protein drug market will reach approximately $248 billion by 2020.

Unfortunately, the manufacture of therapeutic proteins is difficult and complex. According to a report in F1000 Research (Lagasse, Feb 2017), producing a typical protein drug may include more than 5,000 critical process steps. Consequently, even in the best of laboratories, it is not unusual for protein therapeutics to fail in manufacturing. High on the list of reasons for failure are the formation of protein aggregates and the misfolding of the therapeutic protein during the manufacturing process.

Dr. Alexander Lazarev, Vice President of R&D, said: “PreEMT is a patented technology that employs high pressure for the disaggregation and controlled refolding of proteins to their native structures at yields and efficiencies not achievable using existing technologies. PreEMT results in the dissolution of protein aggregates, which may have a significant impact on the quality of protein drugs by improving protein activity, homogeneity, and stability, as well as by reducing undesirable immunogenic properties.”

Dr. Lazarev continued: “PreEMT can be applied to many therapeutic proteins. It can be used to reduce aggregate levels in bulk or final formulations, thereby improving product safety. It is scaleable and practical for standard manufacturing processes. Thus, we believe this unique technology platform can help protein-based biopharmaceutical companies create and manufacture high quality novel protein therapeutics and lower the cost of existing formulations.”

Dr. Nate Lawrence, Vice President of Marketing and Sales commented: “We purchased all assets of BaroFold, Inc. less than five months ago. The development of our Biologics Contract Services Group and associated PreEMT application protocols have just been established at PBI. We are still developing a comprehensive worldwide marketing campaign for the PreEMT platform. To have an international biopharmaceutical company developing protein-based drugs approach us so soon after the purchase of the BaroFold IP estate, says a lot to us about the current needs of protein drug manufacturing and the reputation that the PreEMT platform has already gained in this area.”

Mr. Richard T. Schumacher, President and CEO, said: “We believe this contract will take three to four months to complete. Moreover, we have recently been contacted by several additional biopharmaceutical companies interested in evaluating our PreEMT disaggregation and refolding service in the development and manufacture of protein-based therapeutics. Because of this early interest in the PreEMT platform, and because the BaroFold pressure-based technologies work on and will help sell our existing Barocycler instrumentation, we believe the BaroFold asset purchase will pay for itself very quickly. Finally, and importantly, should the PreEMT technology result in more efficient production of high quality protein-based therapeutics for any biopharmaceutical company developing new protein-based therapeutics, manufacturing-scale licenses have the potential to generate millions of dollars in annual royalty revenue.”

About PreEMT™

PreEMT (“Pressure Enabled Protein Manufacturing”) is a patented technology that employs high pressure for the disaggregation and controlled refolding of recombinant proteins into their native structures for desired drug activity. The PreEMT technology platform is transformative and practical for biopharmaceutical manufacturing processes, offering substantially reduced production costs due to its increased process yield and throughput at high protein concentrations. The PreEMT technology is easily scalable and has been utilized for the cGMP production of phase 1 through phase 3 clinical materials.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT™ technology from BaroFold, Inc. to allow immediate entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

Statements contained in this press release regarding PBI’s intentions, hopes, beliefs, expectations, or predictions of the future are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company’s current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

Investor Contacts:

Richard T. Schumacher, President & CEO Pressure BioSciences, Inc.

Alexander Lazarev, Ph.D., VP of Research and Development (508) 230-1828 (T)

$ETST Poised to Benefit from Fast Growing Hemp-Derived CBD Market

May 3, 2018

• 12 more U.S. states likely to approve medicinal or recreational use of cannabis in 2018
• Hemp-derived CBD market on course for CAGR of 55 percent over next five years
• Ventures in both MMJ and recreational marijuana hedge bets

The tide of cannabis legalization sweeping over North America continues to rise despite intractable federal prohibition in the United States. In the U.S., 29 states and the District of Columbia allow cannabis for medical use. In nine of those jurisdictions, adult recreational use is also permitted. Another 12 are considering easing restrictions on cannabis use by the end of the year. In Canada, the recreational market is set for opening by fall. As a result, the cannabis market outlook is bright. A recent report valued the global legal cannabis market at $14.3 billion in 2016 and projected a compound annual growth rate (CAGR) of 21.1 percent until 2024, to reach $63.5 billion (http://nnw.fm/Z3jbp). In the fastest growing segment of this market is where you will find innovative biotechnology company Earth Science Tech, Inc. (OTC: ETST). The hemp-derived CBD market, in which it operates, is ballooning at a CAGR of 55 percent. At that rate, it will cross the billion-dollar mark in five years. With its ventures in leading edge, cannabinoid-based pharmaceutical and nutraceutical products, ETST is poised to share in that market growth.

Fuel is being added to the cannabis fire. In November 2018, initiatives allowing recreational use are likely to be on the ballot in six states, including Connecticut, Delaware, Michigan, New Jersey, Ohio and Rhode Island. Vermont has already been there and done that. In January 2018, the state legislature passed a bill allowing recreational use, the first and only state to do so prompted by legislative initiative, rather than by being put to voters at ballot. In five more states – Kentucky, Missouri, Oklahoma, South Dakota and Utah – legalization questions on medical marijuana may face voters in November 2018, according to Newsweek (http://nnw.fm/1JDie). If cannabis continues on its roll, 41 states and DC will have legalized cannabis for medicinal purposes, while 15 and DC will permit adult recreational use, by the end of 2018.

To enter this brave new world of cannabis liberalization, ETST is developing a portfolio of new products while aggressively pursuing growth through joint ventures and acquisitions. In this vein, newly created division Cannabis Therapeutic Inc. will develop proprietary cannabinoid-based nutraceuticals and pharmaceutical products based on an existing CBD patent. The company continues its activities in the hemp-derived cannabinoid (CBD), nutraceutical, pharmaceutical and medical device markets. In addition, it is pursuing a vigorous program of R&D and continued development of its marketing and distribution channels.

The company’s purchase of Canna Inno Laboratories Inc. is already paying off. The acquisition, partly designed to gain access to Canadian government funding, has scored on that front. In March 2018, ETST announced that Canna Inno Laboratories had received a supporting grant for innovation in the pharmaceutical industry from the Ministère de l’économie, des sciences et de l’innovation of the Government of Québec.

This first grant is earmarked for the pre-launch processes on the company’s three CBD-based nutraceutical provisional patent products. The pre-launch process includes a series of pre-clinical in vitro trials to fight breast cancer and neurodegenerative disorders. Thereafter, patent applications will be submitted, with the products expected to be commercialized as nutraceuticals during the waiting period. The company also plans to apply for more funding under Canada’s Scientific Research and Experimental Development Tax Credit program, among others. Earth Science expects that, through this new subsidiary, about half of all R&D expenditures will be covered by grants.

ETST is also venturing into the recreational market. A joint venture with Karmavore SuperFood is set to manufacture a new chocolate product, and one with Varsity Group, LLC, a kanna ingredient based e-liquid company, will give Earth Science a presence in the recreational vape/smoke market.

For more information, visit the company’s website at www.EarthScienceTech.com

More from NetworkNewsWire

• Sharing Services Inc. (SHRV) Emerging as Multi-Channel Leader in Direct Sales Marketplace
• QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX.V: QMC) (FSE: 3LQ) Eyeing Lithium Potential at Irgon Mine Project
• Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters License Agreement with California Cannabis Beverage Maker

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$SNNVF Chooses Okanagan Falls Property for Canadian Facility

Vancouver, British Columbia–(May 3, 2018) – Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) (“Sunniva” or the “Company“) is pleased to announce that it has selected the 126 acre Okanagan Falls, British Columbia site to build its Sunniva Canada Campus. The Company’s wholly-owned subsidiary, Sunniva Medical Inc. (“SMI“), has entered into a purchase and sale agreement to acquire the entire 126-acre industrial zoned property for a purchase price of $7 million.

As part of the site selection process, the Company reviewed several options, including leasing land from the Osoyoos Indian Band in Senkulmen Business Park, Oliver, British Columbia. After consideration of a number of factors, including the ability to purchase and own the land and future expansion opportunities, the Company determined that the Okanagan Falls site provides superior benefits and flexibility.

Sunniva is also pleased to announce that it has selected the following vendors in respect of the project:

• Certhon Projects B.V. — supplier of the greenhouse superstructure, electrical, irrigation systems, lighting system and heating, cooling and CO² systems.
• EllisDon Corporation — construction manager and general contractor.
• MQN Architects — architect consultant.
• Urban Systems Ltd. — civil and landscape engineers.

The Company’s preliminary due diligence review of the property has been completed; however, the acquisition remains conditional upon finalization of certain due diligence items and other closing conditions customary in transactions of this nature. Closing is expected to occur on or about June 15, 2018. Pursuant to the terms of the agreement, grading work has commenced on the property and the Company has submitted its development applications in advance of the closing date.

About Sunniva Inc.

Sunniva, through its subsidiaries, is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets — Canada and California — where we are committed to delivering safe, high-quality products and services at scale. Our vision is to become the lowest cost, highest quality cannabis producer in the markets we serve by building large scale purpose-built current good manufacturing practices greenhouses, offering better quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education and sourcing better therapeutic delivery devices. Sunniva’s management and board of directors have a proven track record for creating significant shareholder value both in the healthcare and biotech industries.

Sunniva operates through its wholly owned subsidiaries:

Sunniva Medical Inc. — SMI is a late stage Access Cannabis for Medical Purposes Regulations (“ACMPR“) applicant in final review and is building the Sunniva Canada Campus, 700,000 square feet of purpose-built cGMP compliant greenhouse facilities in British Columbia. The total campus is expected to produce over 100,000 kg of premium medical cannabis a year and over 25,000 kg of trim used for extraction. The facility will produce pesticide free products and will convert trim to extracted products such as cannabis oil. The oil can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams. As the facility is not yet under construction, revenue and costs are not known, therefore, profitability cannot be assured.

CP Logistics, LLC (“CPL“) — Through CPL, Sunniva has commenced construction of the Sunniva California Campus, state-of-the-art, purpose-built greenhouse facilities in Cathedral City, California. The Sunniva California Campus is planned in two phases and has been cGMP designed. Phase 1 is designed to be 325,000-square feet producing in excess of 60,000 kg of premium cannabis a year. The total campus is expected to produce over 100,000 kg of premium cannabis a year after Phases 1 and 2 are complete. At this facility, it is estimated 30% of all product will be used for higher margin extracted products and all products will be produced free from the pesticides commonly used within today’s industry. As the facility is not complete, revenue and costs are not known, therefore, profitability cannot be assured.

Natural Health Services Ltd. (“NHS“) — NHS owns and operates a network of 7 clinics in Canada specializing in medical cannabis under ACMPR. NHS connects patients with safe and effective medical cannabis products through Licensed Producers (“LPs“). NHS has in-house physicians and nurse practitioners specializing in the endocannabinoid system providing expert consultation, education, and recommendations for patients. NHS’ proprietary technology infrastructure assists physicians, patients and LPs to comply with the rules of Health Canada. NHS has more than 150,000 active medical documents outstanding and 95,000 active patients.

Full-Scale Distributors, LLC (“FSD“) — FSD, through its brand, Vapor Connoisseur, is a provider of custom, private-label vaporizers and accessories. FSD currently serves the needs of over 80 brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative vaporization devices. Products are tailored to client needs, ensuring both safety and reliability and FSD will continue to provide these services in coordination with the large supply from both Sunniva Campuses.

For more information please visit: www.sunniva.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding relating to the closing conditions of the property purchase, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, statements regarding Sunniva’s plan to cultivate, produce and distribute a broad range of solutions focused on patients’ needs and Sunniva’s plans, timing and estimates of production for its facilities, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the risk factors included in the Sunniva’s continuous disclosure documents available on www.sedar.com. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Although Sunniva has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. Sunniva assumes no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

Contact Information:
Dr. Anthony Holler
Chairman and Chief Executive Officer

Investor Relations Contact:
George Jurcic
Manager, Investor Relations
587-430-0680
ir@sunniva.com

Corporate Communications Contact: 
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$VSQTF Invests in Top Three Companies at World Blockchain Forum

VANCOUVER, British Columbia, May 02, 2018 — Victory Square Technologies Inc. (“Victory Square” or the “Company”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) returns from the World Blockchain Forum: Investments & ICOs Conference in Dubai, United Arab Emirates, with newly-formed partnerships and investments in three promising blockchain companies that won awards for their presentations in Dubai.

The longest-running and highest-attended financial conference for the bitcoin, blockchain and cryptocurrency industries in the Middle East saw over 1,000 attendees converge in Dubai for the two-day event that took place April 16 and 17, 2018. It saw Victory Square partner with Keynote, the World Blockchain Forum to present the top 3 ICOs Award at the event. The three emerged from the 30 companies that were vetted and selected by the World Blockchain Forum to present their ICOs (with those 30 drawn from an initial pool of applicants).

Victory Square management viewed the presentations of the 30 ICO attendees and conducted Q&A sessions with the management teams of the shortlisted companies. Through this vetting process, Victory Square identified three companies as the top 3 ICOs – companies with which they will explore further relationships. Each of the identified companies will receive $33,000 towards the private sale of their respective tokens. In exchange, Victory Square will receive discounted tokens in the companies’ private pre-sale.

The top 3 companies selected by Victory Square management to share in the $100,000 investment prize pool were: SBC Platform, CryptoCurve, and Paytomat.

Peter Smyrniotis, a member of the Board of Directors of Victory Square, also presented at the conference, outlining Victory Square’s involvement in the blockchain industry and its track record of incubating some of the most promising and disruptive companies.

“This year’s World Blockchain Forum in Dubai featured yet again an impressive collection of the most forward-thinking minds in the blockchain industry,” said Smyrniotis. “We are very proud to be partnered with some of the brightest visionaries on the forefront of this technological revolution. Victory Square’s continued growth and success have been well met by our peers, and we have received strong validation and support for the global brand that we are building. The ability to share our vision and collaborate with other like minds provides the backbone of the structure that will support the technological world in the years to come.”

About the Top Three ICO Award Winners:

PAYTOMAT (www.paytomat.com)
Paytomat offers real life applications to various cryptocurrencies by enabling local stores and online merchants to accept payments in crypto. They serve as a liquidity network, a point of sale interface, a smart asset platform and provide a loyalty program with incentives for merchants and customers alike. Over 150 merchants already use the platform in the Ukraine and are looking to go international.

“We are very thankful to be selected as one of the winners of this year’s competition. We thank the organizers, Victory Square, and the judges for this competition as it is a brilliant place to be to showcase what we have been working very hard to achieve,” said Yurii Olentir, co-founder of Paytomat.

CryptoCurve (https://www.cryptocurve.io)
CryptoCurve offers what is called the Curve Wallet; “The Browser to Blockchain”. It aims to be the first and last wallet an investor will ever need and offers a wide array of next gen features that are industry firsts. Curve will be the first wallet to tie multiple blockchains to a decentralized network of buyers and sellers and provide the ability for 3rd party partners to build on top of their front end. This all-in-one solution further enables users to invest in ICOs, Stake ICOs, pool ICOs, while acting as a fiat gateway that tracks user portfolio values in real time.

“We extend our thanks to Victory Square and the partners who organized this event. We could not ask for a better public debut by being selected as best ICO pitch at the World Blockchain Forum of 2018 in Dubai,” said Joshua Halferty, CEO of CryptoCurve. “It was a pleasure to present in front of this incredible audience and cannot wait for what the future has in store for this team as we bring our Curve Wallet to the masses in the near future.”

SBC Platform (www.sbcplatform.com)
The SBC Platform aims to be the world’s first automated ICO solution for startups and SMEs. Over 20 industry professionals work on this platform to achieve a groundbreaking reduction in the cost of preparing quality projects for the ICO market by using cutting-edge technology. This product will help enable business people to carry out expert evaluation of their business concept, get legal advice and, having prepared all relevant documents for ICO launch based on the platform, to inform prospective backers on their project. Their strategic objective is to serve as a powerful driver for the development of startups, small and medium sized businesses.

“Being awarded a winner of the ICO pitch competition is a great honour for our team. We extend our thanks to Victory Square and the World Blockchain Forum for putting on this great event,” said Georgy Lapin, CEO and co-founder of SBC Platform. “It was a great pleasure to present alongside these fantastic teams and we are excited to take this experience with us as we move forward. Our focus to be a powerhouse that drives blockchain technology worldwide for SMEs remains unwavering, and we are thrilled that our judges at Victory Square support us.”

Meanwhile, further to the World Blockchain Forum Dubai prize pool, previous tokens that Victory Square purchased have completed their token sales. Bluzelle, Neuromation, GBX, Debitum both completed their sales, cumulatively raising over $100M USD. Victory Square also sponsored the ICO pitch competition at the d10e conference in Tokyo, which took place April 28 – May 1, 2018.

Video of Victory Square presenting at the World Blockchain Forum: Investments & ICOs Conference:
https://www.youtube.com/watch?v=pVy7T6KsM1w&t=2s

For further information about the Company, please contact:

Investor Relations Contact – Prit Singh
Email: prit@victorysquare.com
Telephone: 905-510-7636

Media Contact – Howard Blank, Director
Email: howard@victorysquare.com
Telephone: 604-928-6066

ABOUT VICTORY SQUARE TECHNOLOGIES INC.
Victory Square Technologies is a blockchain-focused venture builder that funds and empowers entrepreneurs to implement innovative blockchain solutions. Victory Square portfolio companies are disrupting every sector of the global economy including Virtual Reality, Artificial Intelligence, Personalized Health, Gaming and Film. Victory Square has a proven process for identifying game-changing entrepreneurs and providing them with the partners, mentorship and support necessary to accelerate their growth and help them scale globally. For more information, please visit www.victorysquare.com.

ABOUT THE CANADIAN SECURITIES EXCHANGE (CSE)
The Canadian Securities Exchange, or CSE, is operated by CNSX Markets Inc. Recognized as a stock exchange in 2004, the CSE began operations in 2003 to provide a modern and efficient alternative for companies looking to access the Canadian public capital markets.

FORWARD-LOOKING INFORMATION
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Victory Square. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square, including future plans. Although Victory Square believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Victory Square can give no assurance that they will prove to be correct. Forward- looking statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

$PVOTF Named to the CSE25 Index

• Pivot Pharmaceuticals attains prestigious CSE25 status
• Recent acquisitions have extended the company’s portfolio in the cannabis space
• Numerous pharmaceutical and nutraceutical products in development pipeline

Canadian biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) announced on March 19, 2018, that it has been named to the CSE25 Index (http://cnw.fm/g1qK7). CSE25 is a conglomerate of the 25 largest companies by market capitalization listed on the Canadian Securities Exchange. This achievement adds to Pivot Pharmaceuticals’ status as a constituent of the CSE Composite Index, which provides a distinctly different risk/return profile than the broad Canadian equity market.

“With an impressive pipeline of bio-cannabis products, a strong intellectual property portfolio of formulation and delivery technologies, and the expected addition of ACMPR licensed Agro-Biotech, we are proud to be recognized as leaders on the Canadian Securities Exchange through our inclusion in the CSE25 Index,” Dr. Patrick Frankham, CEO of Pivot Pharmaceuticals, stated in the news release. “Being among the top 25 performers on the exchange validates our business strategy to become a vertically integrated health and wellness company with a rapidly expanding international presence. With all of the exciting opportunities ahead of us, we believe we will remain a consistent part of the CSE25 Index for years to come as we continue to drive shareholder value.”

In February 2018, Pivot Pharmaceuticals entered into a letter of intent for the acquisition of Agro-Biotech Inc., a cannabis cultivator located in Quebec. Agro-Biotech received its producer’s license on January 12, 2018. On completion of the proposed acquisition, Pivot will be able to conduct research and development and store cannabis derivatives not currently covered under ACMPR regulations. The company will also be in a position to process natural health products and export cannabis oils and concentrates to international markets, once it receives an export permit.

The company’s recent acquisitions also include Thrudermic, LLC, a company based in North Carolina that has developed a transdermal, lipid-based nano-dispersion technology for cannabinoid delivery. Pivot also acquired ERS Holdings, LLC in February 2018, a California-based company that holds patents for the production of powderized cannabis oil that can be added to beverages and baked goods.

Pivot Pharmaceuticals is a Vancouver-based biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals through proprietary drug delivery technologies via medical cannabis product division Pivot Green Stream Health Solutions (“PGS”). In early February 2018, the company announced that it had filed three provisional patents for cannabinoid-based product delivery technologies with the U.S. Patent Office. These are for its innovative transdermal nanotechnology, inhalation and mucus topical delivery platforms. Its BiPhasix™ Transdermal Drug Delivery technology has been tested in clinical trials approved by both the FDA and EMA. This delivery platform provides significant advantages over oral delivery technologies.

Pivot has a number of products in its pipeline that are in various stages of development. These target therapies for pain, inflammation, dermatology, eye disease and cancer supportive care. PGS-N005 is a cannabidiol (CBD)-based topical cream to treat female sexual dysfunction, a disorder that is estimated to affect up to 63 percent of women in the United States (http://cnw.fm/32ENj). The market for female sexual dysfunction disorder therapies is estimated to be more than $4 billion.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

• The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) Completes Successful IPO
• The Green Organic Dutchman Ltd. (TSX: TGOD) Lists on the TSX Today
• Marijuana Company of America, Inc. (MCOA) Set to Profit from the Growth of the Legal Hemp Market

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$CIIX CEO Warren Wang Exclusive New Audio Interview SmallCapVoice.com

AUSTIN, Texas, May 02, 2018 — SmallCapVoice.com, Inc. and ChineseInvestors.com Inc. (OTCQB:CIIX) (“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors announced today that the Company’s CEO, Warren Wang is featured in a new audio interview at SmallCapVoice.com, Inc.

The interview outlining CIIX’s current news and efforts can be heard at https://smallcapvoice.com/blog/5-1-18-smallcapvoice-interview-with-chineseinvestors-com-inc-ciix/.

Warren Wang called in to SmallCapVoice.com, Inc. to go over the recent news and highlights for the Company here in spring of 2018. Recently, the Company announced the new opening of a cryptocurrency and trading courses offered through its newly established Bitcoin Trading Academy LLC beginning in June 2018. Online courses will begin June 9, 2018.  Additional course information will be provided on http://www.newcoins168.com. Mr. Wang also touched on the CBD markets here in the United States and in China, plans to spin out their hemp division, CBD Technology, and much more.

In the interview Mr. Wang stated, “Many investors want to learn more about Cryptocurrency trading, but they are not getting involved because it may appear overwhelming. Our education is for the mainstream investor. Right now, I am not aware of any other companies offering this level of education in cryptocurrency and trading courses. We believe there is a large market for our courses.”

About SmallCapVoice.com. Inc.

SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and its services, please visit http://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/

About ChineseInvestors.com (CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online sales and direct sales of hemp-based products and other health related products.

For more information visit: ChineseInvestors.com

Visit and register https://www.newcoins168.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Subscribe and watch our video commentaries: https://www.youtube.com/channel/UCriTFjFHCvDW_LBhiIeuLlQ/featured

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom

https://www.facebook.com/Chineseinvestors.com.english

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776

Investor Relations:
Alan Klitenic
+1-214-636-2548

Corporate Communications:
NetworkNewsWire (NNW)
New York, New York
http://www.NetworkNewsWire.com
+212-418-1217 Office
Editor@NetworkNewsWire.com

For SmallCapVoice.com

Stuart T. Smith

512-267-2430

info@smallcapvoice.com

$PBIO CEO Hosts Webinar

• Company to Discuss Expected Impact on 2018 Revenue from
• Recent Product Enhancements, New Field Salesforce,
• BaroFold Technology Asset Acquisition, and Newly Issued Patents

SOUTH EASTON, MA / May 2, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry, today announced that Mr. Richard T. Schumacher, President and CEO of PBI, will host a webinar update and live Q&A session for investors on Wednesday, May 2, 2018, at 3:00 pm EDT. The webinar will include discussions on enhancements made to products in the Company’s core Research Products & Services business segment, the Company’s new field salesforce, the acquisition of all assets of BaroFold Corporation, and the issuance of patents on the Company’s cutting-edge Ultra Shear Technology (“UST”) platform. The Company will also offer a brief outlook for the 2018 fiscal year.

RedChip’s Global Online Growth Conference brings together investors and executives of leading small-cap companies, representing a broad spectrum within the small cap sector. More than 10,000 investors attend RedChip’s Online Growth Conference series each year. No registration is required to participate in the conference. Start times are subject to change.

To view the webinar, please visit: https://www.redchip.com.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow immediate entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. http://www.pressurebiosciences.com

Forward Looking Statements

Statements contained in this press release regarding PBI’s intentions, hopes, beliefs, expectations, or predictions of the future are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company’s current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Investor Contacts:

Richard T. Schumacher, President & CEO, PBI (T) 508-230-1828
Victor Roberts, RedChip Companies (T) 407-644-4256 (111)
victor@redchip.com

$SABR Alaska Airlines successfully migrates Virgin America into Sabre

SOUTHLAKE, Texas, May 1, 2018 — Sabre Corporation (NASDAQ: SABR) and Alaska Airlines have successfully migrated Virgin America to Alaska’s passenger services system (PSS), hosted by Sabre. The recently completed migration will allow Alaska and Virgin America to move forward using Sabre systems as one unified airline while offering a seamless, end-to-end guest experience.

“Since initiating the merger with Virgin America, Alaska’s primary focus has been on the 44 million guests that collectively choose our airlines each year – and expanding our technology platform to best serve every one of them,” said Shane Tackett, Alaska Airlines’ senior vice president of revenue management and e-commerce.  “Along with the passion and commitment to a successful migration from our employees, Sabre’s partnership has been invaluable to realizing this mission-critical transition.”

Sabre and Alaska have been engaged for the last year building the foundation for Alaska’s growth and superior customer experience.  The successful migration is an example of the companies’ deeply collaborative relationship. Now that the integration is complete, Alaska will expand its use of Sabre’s customer management technology across the enterprise to fulfill its brand promise, enhance retailing capabilities and offer guests the best options in an ultra-competitive environment.

“Sabre is delighted to continue a rich partnership with Alaska Airlines – which is consistently ranked as one of the top airlines in North America – and assist them in executing their complex merger with Virgin America,” said Jeff Fullmer, vice president and regional general manager, Sabre Airline Solutions, North America.  “We experienced terrific collaboration between our teams throughout the migration process and look forward to supporting Alaska’s ongoing innovation and technology objectives.”

In December 2017, Alaska Airlines renewed its longstanding partnership with Sabre, including access to full content through the global distribution system (GDS) and an expansion of Alaska’s passenger services system. Alaska Airlines and its regional partners fly 44 million guests a year to more than 115 destinations, with an average of 1,200 daily flights across the United States, Mexico, Canada and Costa Rica.

About Sabre

Sabre Corporation is the leading technology provider to the global travel industry. Sabre’s software, data, mobile and distribution solutions are used by hundreds of airlines and thousands of hotel properties to manage critical operations, including passenger and guest reservations, revenue management, flight, network and crew management. Sabre also operates a leading global travel marketplace, which processes more than US$120 billion of global travel spend annually by connecting travel buyers and suppliers. Headquartered in Southlake, Texas, USA, Sabre serves customers in more than 160 countries around the world.

SABR-F

$SNNVF Reports Fiscal 2017 Financial, Operational Results

VANCOUVER, British Columbia, April 30, 2018 — via NetworkWire – Sunniva Inc. (“Sunniva” or “the Company”) (CSE:SNN) (OTCQX:SNNVF), a North American provider of cannabis products and services, today released its financial results and management’s discussion and analysis for the three months and year ended December 31, 2017. All figures are reported in Canadian dollars ($). Sunniva’s financial statements are prepared in accordance with International Financial Reporting Standards.

Message from the CEO

“2017 was a transformative year for Sunniva establishing the necessary infrastructure to become one of the largest vertically integrated cannabis companies operating in the world’s two largest cannabis markets – Canada and California. It has taken us many years to navigate strict federal and state legislative frameworks in California and the recent US presidential support of the legislative rights of individual states affirms our vision of becoming the leading provider of clean, medical grade cannabis within the Golden State,” said Tony Holler, CEO of Sunniva.

“Our vision is to become one of the lowest cost, highest quality cannabis producers in these markets by building large scale purpose-built current good manufacturing practices (“cGMP”) designed greenhouses and establishing sophisticated distribution channels, including our ownership of Natural Health Services (“NHS”) cannabis clinics in Canada which has surpassed 95,000 active patients as of today, to purchase the significant quantities of high quality Sunniva branded and Sunniva private label cannabis products. Our focus moving forward is to execute and de-risk our business model by forward selling a large portion of our production in both markets, supplementing the previously announced 90,000 KG take or pay contract with Canopy Growth in Canada, with an emphasis on creating long term shareholder value.”

“2017 was a year of building and 2018 will be the year of execution for our team to drive significant revenue in the near future. The major focus and milestones for the Company over the next year will be:

• Completing construction and commencing operations in our large-scale cGMP greenhouse facilities in both Canada and California.

• Finalizing debt financing for the estimated $120 million construction costs of the Sunniva Canada Campus.

• Securing additional long-term supply contracts in both markets.

• Leveraging the NHS doctor and software platform to capture a significant percentage of the Canadian medical cannabis market.

• Establishing a global Sunniva brand – a trusted source of high quality cannabis flower and extracted products and services.”

Financial Highlights – Year ended December 31, 2017

Consolidated Financial Highlights Expressed in 000’s of CDN$, except per share amounts

Operating Highlights –  Year ended December 31, 2017

Key operating highlights for the Company for the year included:

• In Cathedral City, California the Company acquired 20 acres of land and 18 licenses to produce and distribute cannabis in California.  The Company subsequently received its Conditional Use Permit from the City of Cathedral City which permitted construction to commence on the Company’s 489,000 square foot purpose-built cGMP designed greenhouse facility.  The facility is being financed by a related party of the Barker Pacific Group, Inc. as part of the sale and lease back of its greenhouse facility.

• The Company acquired NHS, one of the largest aggregators of medical cannabis patients in Canada.

• The Company acquired Full-Scale Distributors, LLC operating through the brand Vapor Connoisseur, a provider of custom private label vaporizers and cartridges to over 80 brands in North America.

• The Company acquired two leases and extraction licenses in Cathedral City for volatile and non-volatile extraction.

• The Company raised approximately $25.7 million in private placement financings of common shares, special warrants and convertible debentures.

Results of Operations – Year Ended December 31, 2017

During Fiscal 2017, the Company completed its first year of revenue generation with a total of $16.1 million in revenue for the year ended December 31, 2017. Revenue was generated from its two acquisitions during the period, NHS and FSD, which contributed $11.3 million and $4.8 million in revenue, respectively. Net loss for the year ended December 31, 2017 was $18.5 million as compared to $6.9 million during the year ended December 31, 2016.

The primary factors affecting the magnitude and variations of the Company’s losses are as follows:

In the year ended December 31, 2017 the Company incurred $14.3 million in selling, general and administrative expenses. The Company also incurred costs of goods sold of $9.4 million on a consolidated basis consisting primarily of contract physician compensation in NHS and product manufacturing costs in FSD.

During the year ended December 31, 2017, the Company incurred non-cash expenses of $6.3 million resulting from a fair value increase in its convertible promissory notes and warrants; an expense of $2.5 million resulting from the amortization of intangible assets acquired with NHS and FSD; and share-based compensation expense of $4.0 million. The expenses were applied to the Consolidated Statements of Comprehensive Loss for the year.

The Company incurred a net loss of $18.5 million for the year ended December 31, 2017. On a comparative basis, the net loss increased from the year ended December 31, 2016 by $11.6 million.

The key components contributing to the change in net loss from the year ended December 31, 2017 compared to the year ended December 31, 2016 was comprised of the following:

• Expense due to the revaluation of secured convertible promissory notes and warrants of $6.3 million that occurred in the year ended December 31, 2017.

• Costs of goods sold increased from $nil to $9.4 million resulting from the revenue generating activities of NHS and FSD.

• An increase in costs related to selling, general and administration expenses from $3.6 million to $14.3 million due to the acquisition of two operating companies NHS and FSD and the Company’s overall growth.

• Expenses for the period resulting from the amortization of acquired intangible assets in the amount of $2.5 million for the year ended December 31, 2017.

• Expenses were offset by an increase in revenue from $nil to $16.1 million the year ended December 31, 2017. In addition, deferred revenue increased from $nil as at December 31, 2016 to $0.7 million as at December 31, 2017, resulting from customer deposits on sales of merchandise.

Results of Operations – Three Months Ended December 31, 2017

During the fourth quarter of Fiscal 2017, the Company generated $5.9 million in revenue compared to $nil revenue in the fourth quarter of Fiscal 2016. Revenue was generated from its two acquisitions during Fiscal 2017, NHS and FSD, which contributed $3.9 million and $2.0 million in revenue respectively. Net income for the fourth quarter of Fiscal 2017 was $0.2 million as compared to a net loss of $1.4 million during the fourth quarter of Fiscal 2016.

The primary factors affecting the magnitude and variations of the Company’s losses are as follows:

In the fourth quarter of Fiscal 2017 the Company incurred $5.2 million in selling, general and administrative expenses. The Company also incurred costs of goods sold of $3.4 million on a consolidated basis consisting primarily of contract physician compensation in NHS and product manufacturing costs in FSD.

During the fourth quarter of Fiscal 2017, the Company realized a non-cash recovery of $2.4 million resulting from a fair value decrease in its convertible promissory notes and warrant liability; a recovery of $1.4 million resulting from the finalization of the NHS purchase price allocation and the resulting impact on amortization of the intangible software assets; and share-based compensation expense of $0.7 million. The expenses were applied to the Consolidated Statements of Loss and Comprehensive Loss for the period.

The Company earned net income of $0.2 million for the fourth quarter of Fiscal 2017 compared to a net loss of $1.4 million in the fourth quarter of Fiscal 2016. The key components contributing to the change in net loss from the fourth quarter of Fiscal 2017 compared to the fourth quarter of Fiscal 2016 was primarily related to:

• Recovery due to the revaluation of secured convertible promissory notes and warrants of $2.4 million that occurred in the fourth quarter of Fiscal 2017.

• Costs of goods sold increased from $nil to $3.4 million resulting from the revenue generating activities of NHS and FSD.

• An increase in costs related to selling, general and administration expenses from $0.9 million to $5.2 million due to the acquisition of two operating companies NHS and FSD, share-based compensation and the Company’s overall growth.  This was offset by an increase in revenue from $nil to $5.9 million in the period.

• Recovery for the period resulting from the amortization of acquired NHS software in the amount of $1.9 million for the fourth quarter of Fiscal 2017.

Recent Operating Developments Subsequent to December 31, 2017

For a comprehensive overview of Sunniva’s Recent Developments, please refer to the Company’s Management’s Discussion and Analysis of the Financial Condition and Results of Operations for the Three and Twelve Months Ended December 31, 2017.

• On January 10, 2018, the Company began trading its common shares on the Canadian Securities Exchange under the symbol “SNN”. On February 15, 2018 the Company began trading its common shares on the OTCQX Market, operated by OTC Markets Group, under the symbol “SNNVF”.

• On February 21, 2018 Sunniva and Canopy Growth Corporation (“Canopy Growth”) entered into a take or pay supply agreement. Under the terms of the agreement, Canopy Growth will purchase up to 45,000 kilograms of dried cannabis annually which includes Canopy Growth purchasing and distributing Sunniva branded products.  Canopy Growth and Sunniva will share in the revenues as product is sold through Canopy Growth’s distribution network including its online marketplace, Tweed Main Street and via provincial distribution channels. The revenue share will be based on the strain, sales channel and other relevant factors.

• On February 15, 2018, the Company repaid the FSD note in cash of $2.8 million (US$2.2 million), plus accrued interest, and the remaining portion through the issuance of common shares at the conversion price of US$2.55 per share.

• On March 27, 2018 the Company completed a bought deal public offering for aggregate gross proceeds of $27.8 million. A total of 2,850,900 units (“Units”) and 50,000 Warrants (as defined below) were sold at a price of $9.75 per Unit and $0.02 per Warrant. Each Unit consists of one Common Share in the capital of the Company and one-half of one common share purchase warrant (each whole warrant, a “Warrant”) of the Company. Each whole Warrant shall entitle the holder thereof to acquire one common share at an exercise price per share of $12.50 for a period of 24 months.

• On April 12, 2018, Sunniva announced that its US subsidiaries received all the necessary State of California temporary licenses for phase one and two for its purpose built state-of-the-art greenhouse cultivation facilities in Cathedral City, California.

Copies of our audited annual financial statements and related management’s discussion and analysis of financial results are available on SEDAR at www.sedar.com.

About Sunniva Inc.

Sunniva, through its subsidiaries, is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – where we are committed to delivering safe, high-quality products and services at scale.  Our vision is to become the lowest cost, highest quality cannabis producer in the markets we serve by building large scale purpose-built current good manufacturing practices greenhouses, offering better quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education and sourcing better therapeutic delivery devices.  Sunniva’s management and board of directors have a proven track record for creating significant shareholder value both in the healthcare and biotech industries.

Sunniva operates through its wholly owned subsidiaries:

Sunniva Medical Inc. (“SMI”) – SMI is a late stage Access to Cannabis for Medical Purposes Regulations (“ACMPR”) applicant in final review and is building the Sunniva Canada Campus, 700,000 square feet of purpose-built cGMP compliant greenhouse facilities to be located in British Columbia. The total campus is expected to produce over 100,000 kg of premium medical cannabis a year and over 25,000 kg of trim used for extraction. The facility will produce pesticide free products and will convert trim to extracted products such as cannabis oil. The oil can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams. Sunniva anticipates breaking ground in the next two weeks. As the facility is not yet under construction, revenue and costs are not known, therefore, profitability cannot be assured.

CP Logistics, LLC (“CPL”) – Through CPL, Sunniva has commenced construction of the Sunniva California Campus, state-of-the-art, purpose-built greenhouse facilities in Cathedral City, California. The Sunniva California Campus is planned in two phases and has been cGMP designed. Phase 1 is designed to be 325,000-square feet producing in excess of 60,000 kg of premium cannabis a year. The total campus is expected to produce over 100,000 kg of premium cannabis a year after Phases 1 and 2 are complete. At this facility, it is estimated 30% of all product will be used for higher margin extracted products and all products will be produced free from the pesticides commonly used within today’s industry.  As the facility is not complete, revenue and costs are not known, therefore, profitability cannot be assured.

Natural Health Services Ltd. (“NHS”) – NHS owns and operates a network of 7 clinics in Canada specializing in medical cannabis under ACMPR.  NHS connects patients with safe and effective medical cannabis products through Licensed Producers (“LPs”). NHS has in-house physicians and nurse practitioners specializing in the endocannabinoid system providing expert consultation, education, and recommendations for patients. NHS’ proprietary technology infrastructure assists physicians, patients and LPs to comply with the rules of Health Canada. NHS has more than 150,000 active medical documents outstanding and 95,000 active patients.

Full-Scale Distributors, LLC (“FSD”) – FSD, through its brand, Vapor Connoisseur, is a provider of custom, private-label vaporizers and accessories. FSD currently serves the needs of over 80 brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative vaporization devices. Products are tailored to client needs, ensuring both safety and reliability and FSD will continue to provide these services in coordination with the large supply from both Sunniva Campuses.

For more information please visit: www.sunniva.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, statements regarding Sunniva’s plan to cultivate, produce and distribute a broad range of solutions focused on patients’ needs and Sunniva’s plans, timing and estimates of production for its facilities, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the risk factors included in the Sunniva’s continuous disclosure documents available on www.sedar.com. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Although Sunniva has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. Sunniva assumes no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

Contact Information:
Dr. Anthony Holler
Chairman and Chief Executive Officer

Investor Relations Contact:
George Jurcic
Manager, Investor Relations
587-430-0680
ir@sunniva.com

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$NETE PayOnline Partners with Bank Sputnik

MIAMI, FL, May 01, 2018 — Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a global technology and value-added solutions group that supports electronic payments acceptance in a multi-channel environment including point-of-sale (POS), e-commerce and mobile devices, today announces that its PayOnline subsidiary is partnering with Bank Sputnik to offer a comprehensive multi-channel payment facilitator solution for SMB merchants in the Russian Federation.  This unique solution offers a set of tools not available from any other transaction processing company in the region and expands PayOnline’s offerings beyond electronic commerce.

Bank Sputnik has entered into an exclusive partnership with PayOnline to offer a fully compliant legal framework and bank sponsorship to enable PayOnline to process transactions as a payment facilitator.  By provisioning a single, master merchant ID, PayOnline ensures merchants and their clients benefit from an automated, real-time and seamless onboarding experience. The API-driven platform simplifies merchant account enrollment.  A sub-merchant can be enrolled, approved, boarded and processing payments in a few minutes.

PayOnline merchants have instant access to a suite of value-added merchant solutions which include credit card auto account updater, multi-currency pricing, tokenization, advanced fraud detection tools and smart transaction routing. According to Statista Digital Markets report, the total transaction value in digital payments segment in Russia will amount to US$39.5 billion in 2018, up from US$27.9 billion in 2016. Total transaction value is expected to show an annual growth rate (CAGR 2018-2022) of 11.9% resulting in the total amount of US$61.8 billion in 2022.

“This innovative, turnkey solution offers frictionless onboarding for merchants with integrated, value-added services,” commented Andrey Krotov, CTO of Net Element. “With customizable payment flows, full-stack API and value-added solutions, PayOnline exceeds the unique needs of software platforms and merchants looking to enable payments in a multi-channel environment.”

About Bank Sputnik
Commercial “Sputnik” Bank was founded in 1990. Today, ” Sputnik” – is a universal bank providing a full range of banking services to both legal entities and individuals. The service package includes payment, credit, deposit, documentary and other operations carried out in Russian and foreign currencies. Further information is available at www.banksputnik.com.

About Net Element
Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. In the U.S. it aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, our cloud based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500™.  In 2017, Net Element  was recognized by South Florida Business Journal as one of 2016’s fastest growing technology companies. Further information is available at www.NetElement.com.

Forward-Looking Statements
Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include to whether the partnership with Bank Sputnik will be successful or yield any benefits to teh Company.  Additional  examples of such risks and uncertainties include, but are not limited to: (i) Net Element’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element’s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element’s ability to successfully expand in existing markets and enter new markets; (iv) Net Element’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element’s business; (viii) changes in government licensing and regulation that may adversely affect Net Element’s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element’s business; (x) Net Element’s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk of further U.S. government sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Net Element, Inc.
1-786-923-0502
media@netelement.com

$DJACF Files Fiscal Year 2017 Results

Hiku closes the year poised for the adult use market in Canada

TORONTO, May 1, 2018 – Hiku Brands Company Ltd. (CSE: HIKU) (“Hiku” or the “Company”) is pleased to announce the filing of its financial statements and management discussion and analysis for the fiscal year ending December 31, 2017. These filings are available for review on SEDAR.

“2017 was a transformational year as we worked to establish a solid foundation for Hiku leading into Canada’s upcoming legalization of adult use cannabis,” said Alan Gertner, CEO of Hiku Brands. “In 2018, Hiku continues its mission to add to its portfolio of iconic brands, grow its retail footprint and enter into partnerships to advance the vision of becoming the preeminent vertically integrated cannabis brand house. With our recently announced merger with WeedMD, Hiku will immediately add 1,500 kg of indoor annual cannabis production capacity, fully funded production expansion capacity of more than 50,000 kg/yr and a well known, highly regarded medicinal brand. From our products to our in-store experiences, the combined company is poised to be a formidable force in the cannabis industry.” 

Fiscal Year 2017 Highlights

June

• Received License to Cultivate – Hiku’s wholly-owned subsidiary, DOJA Cannabis Ltd. (“DOJA”), received its license to cultivate under the ACMPR (Access to Cannabis for Medical Purposes Regulations) from Health Canada;

August

• Go-public – Completed a go-public transaction on the Canadian Securities Exchange

October

• Completed First Harvest – Harvested and cured DOJA’s first batches of premium handcrafted cannabis flower in October at its Dominion facility in West Kelowna, British Columbia (with annual production capacity of 660 kg of dried flower);
• First DOJA Cafe Opened – Opened the first DOJA Cafe, a retail store in downtown Kelowna, focused on building brand awareness, cannabis education, and medical patient pre-registration. The location is non-cannabis dispensing and sells artisanal coffee, clothing and accessories;
• Secured Expansion Property – Purchased a building and land out of receivership in Kelowna, British Columbia, home to DOJA’s second site facility (the “FUTURE LAB”), which is anticipated to expand annual corporate production capacity by an additional 4,500 kg;

November

• FUTURE LAB Construction – Commenced construction on the FUTURE LAB, the facility will incorporate solar power, LED lighting, two-tier vertical farming and a state-of-the-art extraction lab;

December

• Imported Cannabis Seeds – Received an import permit from Health Canada for cannabis seeds to build DOJA’s genetics library to differentiate the brand, not only through its products and approach to the market, but also by curating a diverse and proprietary cultivar offering;
• Raised $20 Million – Strengthened the Company’s balance sheet by a total of $20 million through equity and convertible debt financings;
• DOJA & Tokyo Smoke Merger – Announced a transformational merger of DOJA and TS Brandco Holdings Ltd. (“Tokyo Smoke”), bringing together industry leading management teams, British Columbia curated handcrafted cannabis production, a portfolio of visionary brands and a growing nationwide retail footprint; and
• Aphria Strategic Investment – Announced a strategic financing of $12.5 million led by Aphria Inc. (Hiku subsequently closed the financing on January 9, 2018.)

2018 Highlights to Date

January

• Launched Hiku – The merger of DOJA and Tokyo Smoke closed and the combined company was renamed Hiku Brands Company Ltd. – becoming Canada’s first vertically integrated cannabis brand house and uniting the cannabis brands DOJA, Tokyo Smoke, and Van der Pop;

February

• Added Quebec Brand – Hiku signed a binding LOI with Maïtri Group Inc, a Quebec based cannabis brand, to acquire 100% of the issued and outstanding shares (Hiku subsequently entered into the definitive agreement on April 30);
• Awarded Manitoba Retail License – Tokyo Smoke, with participation of BOBHQ, was conditionally awarded one of four master retail licenses in Manitoba’s Request for Proposal process for the right to operate retail cannabis stores. The license gives Tokyo Smoke the ability to operate legal retail cannabis stores and an online cannabis e-commerce platform in Manitoba;
• Entered into First International Partnership in Jamaica – Hiku entered into a LOI with Kaya Inc., the first licensed medical cannabis producer and dispensary operator in Jamaica, to launch a strategic alliance to pursue medical and adult-use cannabis branding, genetics, and retail opportunities in Jamaica and Canada;

March

• Announced Cannabis Oil Partnership – Signed a strategic partnership agreement with Vitalis Extraction Technology Inc., a Kelowna based company at the forefront of CO2 extraction innovation;
• Bolstered Leadership Team – Made several key additions to the leadership team with significant expertise in retail, branding, government relations and communications;
• Redefining the Cannabis Retail Experience – Entered into an exclusive collaboration agreement with Jackman Reinvention Inc. (a strategic and creative brand consultancy with deep experience in retail execution) to create a blueprint for Hiku’s dispensary build-outs in select provinces;
• Bringing Exceptional Products to Market – Entered into a letter of intent to establish a co-marketing, retail and select distribution relationship with dosist (previously known as hmbldt), a leading wellness brand providing consistent, controlled and effective cannabis-based solutions

April

• Received Sales License – DOJA received an amendment to its sales license from Health Canada to include the sales of dried cannabis, cannabis plants and seeds; and
• Hiku & WeedMD Merger – Hiku entered into a definitive agreement to merge with WeedMD, combining a premium cannabis brand house and retail focused operator in Hiku, with the significant production capabilities and differentiated medical brand in WeedMD. The combined company will have a diversified cannabis cultivation platform with four facilities from coast-to-coast with planned expansion capacity to have the ability to produce over 56,000 kg by mid-2019.

Definitive Agreement with Maïtri

Further to the press release dated February 1, 2018, Hiku is pleased to announce it has entered into a definitive share purchase agreement (the “Share Purchase Agreement”) to acquire 100% of the issued and outstanding shares ofMaïtri Group Inc. (“Maïtri”), a Quebec-based cannabis accessory and design brand (the “Acquisition”).

Pursuant to the Share Purchase Agreement, shareholders of Maïtri will receive upfront consideration of an aggregate of $550,000 in a combination of $50,000 cash and 318,471 Hiku shares (the “Consideration Shares”), and may earn up to an additional 764,329 Hiku shares in earn out and contingent payments if certain performance milestones are met. A portion of the Consideration Shares will be held in escrow and released to the shareholders of Maïtri over twenty-four months following the closing of the Acquisition. The parties intend to proceed to close the Acquisition as soon as possible and in accordance with the Canadian Securities Exchange policies.

About Hiku Brands

Hiku is focused on building a portfolio of engaging cannabis brands, unsurpassed retail experiences and handcrafted cannabis production. With a national retail footprint led by Tokyo Smoke, craft cannabis production through DOJA’s ACMPR licensed grow, and Van der Pop’s female-focused educational platforms, Hiku houses an industry-leading portfolio that aims to set the bar for cannabis brands in Canada.

Hiku’s wholly-owned subsidiary, DOJA Cannabis Ltd., is a federally licensed to cultivate and sell cannabis pursuant to the ACMPR, owning two production facilities in the heart of British Columbia’s Okanagan Valley. Hiku’s wholly-owned subsidiary, Tokyo Smoke has been conditionally awarded one of four master retail licenses in Manitoba. Hiku also operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

Forward-looking statements

This news release contains statements that constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Hiku’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.

Forward-looking statements in this document include, among others, the Company’s expectations concerning the completion of the merger with WeedMD and the planned production capacity of the combined company. By their nature, forward-looking statements are based on the opinions and estimates of management at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Hiku is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.

SOURCE Hiku Brands Company Ltd.

$ETST Aims to Complete White Paper Studies in Early 2019

• ETST will investigate combination drugs that combine a mineral element with full spectrum cannabinoid industrial hemp oil; it anticipates completion of white paper studies in early 2019, with clinical trials to follow
• Goal is to produce both an OTC nutraceutical product and a cannabinoid companion generic drug to fight the epidemic of opioid dependency
• Foundations Wellness Center reports that two million Americans are now addicted to opioids

Earth Science Tech, Inc. (OTC: ETST) has set 2019 as the crucial year when the company anticipates completion of white paper studies and the start of human clinical trials to investigate the synergies of drugs that are intended to treat opioid dependency. It intends to test the effectiveness of combination drugs that contain a mineral element and full spectrum cannabinoid industrial hemp oil (http://cnw.fm/2SaKh).

The clinical trials are expected to commence in 2019 or later. The goal is to produce an over-the-counter (OTC) treatment drug and a cannabinoid companion generic drug to battle opioid dependency. The Foundations Wellness Center reported that two million Americans were addicted to opioids in 2015, the most recent full year for which those statistics are currently available (http://cnw.fm/7Fu55).

The trials are likely to investigate the synergies between mineral elements and cannabinoid industrial hemp oil for use as a treatment for opioid dependency. ETST could then be positioned to bring new products to the marketplace. Per company reports, one drug could be designed to reduce the cravings of opioid addicts and the other, a generic, could make the treatment more effective and reduce the danger of side effects.

Addiction can lead to death from opioids. The Washington Post quotes two specialists as saying that the final death count relating to opioid addiction in 2017 could reach 50,000, higher than the number of AIDS deaths at the peak of that epidemic (http://cnw.fm/52uGE).

ETST is a biotech company focused on the cannabinoid, pharmaceutical and nutraceutical markets, as well as conducting R&D for medical devices. It is a company that holds several operational subsidiaries, including Earth Science Pharmaceutical, Inc.; Cannabis Therapeutics, Inc.; and KannaBidioiD, Inc. In addition, the company holds a Montreal-based subsidiary, Canna Inno Laboratories, Inc., providing access to Canadian grants.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

• Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) Developing Portfolio of Cannabis Companies
• Global Hemp Group, Inc. (CSE: GHG) (FRA: GHG) (OTC: GBHPF) Set to Gain from Hemp Legalization Drive in U.S.
• ChineseInvestors.com, Inc. (CIIX) Eyes Chinese Expansion with Establishment of Shanghai-Based Subsidiary

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$NSPR Regulatory Approval, Reimbursement in Vietnam CGuard EPS™ and MGuard™

InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has received regulatory approval, and has initiated commercialization of its CGuard™ Embolic Prevention System (EPS) and MGuard Prime™ in Vietnam.  Both of these devices utilize the company’s patented MicroNet™ technology.

“Our ability to initiate commercialization for both of the company’s devices was due to our capability to coordinate getting three key elements in place concurrently and quickly. Specifically, we secured regulatory approval, a valid import license and product reimbursement, all of which come from Vietnam’s Department of Medical Equipment and Health Works (DMEHW), a unit of the Ministry of Health (MOH). Part of this effort was coordinated by DO GIA, our recently appointed distributor in Vietnam. DO GIA has an established distribution network across Vietnam that covers both physicians, clinics and hospitals. With a population of over 100 million people, Vietnam represents another important step forward in our focused expansion across Asia,” commented Agustin Gago, Chief Commercial Officer of InspireMD.

CGuard™ EPS is a carotid embolic protection system that is designed to deliver the company’s self-expanding stent wrapped in the company’s proprietary MicroNet™ technology to the carotid arteries using a rapid exchange delivery system to prevent embolic events that can lead to stroke. The MGuard Prime™ coronary stent system consists of the company’s coronary balloon expandable stent wrapped with MicroNet™ pre-mounted on a rapid exchange balloon catheter, that prevents embolic events in the heart that can result in myocardial infarction, heart failure and even death. Both products are now being sold in a variety of markets across Europe, Middle East, Asia and Latin America.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:

InspireMD, Inc.

Craig Shore

Chief Financial Officer

Phone: 1-888-776-6804 FREE

Email: craigs@inspiremd.com   

Crescendo Communications, LLC

David Waldman

Phone: (212) 671-1021

Email: NSPR@crescendo-ir.com

$ATOS Approval from Swedish Medical Products Agency for Endoxifen Study

Study’s Endpoints Are Changes in Mammographic Breast Density, Tolerability, and Safety

SEATTLE, April 30, 2018 — Atossa Genetics Inc. (Nasdaq:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, announced today that it has received approval from the Swedish Medical Products Agency (MPA) to conduct a Phase 2 Study of its proprietary topical Endoxifen for the treatment of women with mammographic breast density, or MBD. Studies by others have shown that a reduction in MBD reduces the risk of developing breast cancer and may potentially improve the accuracy of mammography in finding cancer.

The Phase 2 study will be conducted at Stockholm South General Hospital in Sweden and will be led by principal investigator Dr. Per Hall, MD, Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet. Atossa plans to open the study for enrollment this quarter.

The primary endpoint is individual change in MBD, which will be measured after three and six months of entering the study, and the secondary endpoints are safety and tolerability. Ninety participants will be randomized to one of three groups (one placebo group and two groups on different doses of topical Endoxifen) with 30 participants per group. The objective of the study is to determine the effect size of breast density between the topical and active groups, which will permit sample size calculations in a future Phase III study.

“Dr. Hall is widely regarded as a leading researcher in the field of breast cancer and prevention. He is heading the unique KARMA (Karolinska Mammography Project for Risk Prediction of Breast Cancer) Cohort, including over 70,000 women, which is regarded as the best characterized breast cancer cohort in the world and serves as a resource for studies about breast cancer risk assessment and prevention, and the Karisma Intervention Study, which is studying the change in MBD in women taking various doses of oral tamoxifen. We are honored to be working with Dr. Hall and his colleagues on our Phase 2 study of MBD as their unique experience and qualifications are simply unmatched anywhere in the world,” said Dr. Steven C. Quay, CEO and President of Atossa.

Atossa’s Proprietary Endoxifen

Endoxifen is an active metabolite of tamoxifen. Tamoxifen is an FDA-approved drug to prevent new breast cancer as well as recurrent breast cancer in breast cancer patients. Tamoxifen itself must be broken down by the liver into active compounds (metabolites), of which Endoxifen is the most active. Atossa has completed a comprehensive Phase 1 clinical study using both a topical and an oral formulation of Endoxifen. Preliminary results from the topical arm of the study indicated that the topical formulation was safe, well tolerated and that topical Endoxifen crossed the skin barrier in a dose-dependent fashion.

Topical Endoxifen Opportunities

Atossa is developing its proprietary topical Endoxifen to reduce MBD, which has been shown in studies conducted by others to be an independent risk factor for developing breast cancer. To date, 30 U.S. states require that findings of MBD be directly communicated to the patient. Although oral tamoxifen has been shown to reduce MBD, the benefit-risk ratio is generally not acceptable to most physicians and their patients. For example, it is estimated that only ~ 2% of women at high-risk of developing breast cancer, including those with MBD, take oral tamoxifen to prevent breast cancer because of the risks of, or actual side-effects of, oral tamoxifen.

Atossa is also developing topical Endoxifen for a condition in men called gynecomastia, which is male breast enlargement, which affects 25% of men between the ages of 50-69.  Atossa has commenced a Phase 1 study in men using topical Endoxifen, which it plans to fully-enroll this quarter.

Oral Endoxifen Opportunity

Approximately one million breast cancer survivors take oral tamoxifen annually; however, up to half of them do not properly metabolize tamoxifen and do not have desired levels of Endoxifen (meaning they are “refractory”). Low Endoxifen levels in breast cancer patients taking oral tamoxifen are associated with an increased risk of recurrence or the development of new breast tumors. Providing oral Endoxifen directly to the patient without having to be metabolized by the liver may help to address this problem.

Based on the number of women at high-risk of developing breast cancer and the number of patients who have survived breast cancer but are refractory to tamoxifen, Atossa estimates that the potential markets for its proprietary oral and topical formulations of Endoxifen could each potentially exceed $1 billion in annual sales.

The Medical Products Agency

The Medical Products Agency is the government agency in Sweden responsible for regulation and surveillance of the development, manufacturing and sale of medicinal drugs, medical devices and cosmetics.

The Swedish Medical Products Agency is one of the leading regulatory authorities in the EU. During the last five years, the Swedish MPA has been among the top three agencies in Europe, counting the number of approval processes managed for central (i.e. European) approvals of medicines. The Swedish MPA also has strong representation in more than 110 working groups and committees in the scope of the Heads of Medicines Agencies (HMA) and European Medicines Agency (EMA) for regulation of medical products in Europe.

The Medical Products Agency is a government body under the aegis of the Swedish Ministry of Health and Social Affairs. Its operations are largely financed through fees. Approximately 750 people work at the agency; most are pharmacists and doctors.

Breast Cancer Statistics

The American Cancer Society (ACS) estimates that approximately 268,000 women will be diagnosed with breast cancer in the United States this year and that approximately 41,000 will die from the disease. It is the second leading cause of cancer death in American women. Although about 100 times less common than women, breast cancer also affects men. The ACS estimates that in 2018 2,550 new cases of invasive breast cancer will be diagnosed in men; and 480 men will die from breast cancer.

About Stockholm South General Hospital

Stockholm South General Hospital is one of the largest hospitals in Sweden, offering care to more than two million Stockholmers. It is one of four hospitals collaborating with Karolinska on the KARMA project. For more information, please visit http://www.sodersjukhuset.se/Functions/InEnglish/.

About Karolinska Institutet

Karolinska Institutet, located in Stockholm, Sweden, is one of the world’s foremost medical universities. Its vision is to make a significant contribution to the improvement of human health; its mission is to conduct research and education and to interact with the community. As a university, KI is Sweden’s single largest center of medical academic research and offers the country’s widest range of medical courses and programs. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine. For more information, please visit www.ki.se/en and www.KARMAstudy.org.

About Atossa Genetics

Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa’s drugs under development and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Genetics Company Contact:

Atossa Genetics Inc.
Kyle Guse
CFO and General Counsel
(O) 866 893-4927
kyle.guse@atossagenetics.com

Investor Relations Contact:

Scott Gordon
CoreIR
377 Oak Street
Concourse 2
Garden City, NY 11530
Office: 516 222-2560
scottg@CoreIR.com

$NETE Multi-Channel Platform Offering Simplified End-to-End Payment Processing

April 30, 2018

• Netevia offers full integration with all major platforms, with the possibility of expanding compatibility in the future
• Instant onboarding, three-hour funding time, enhanced security and payment conversion optimization are among platform’s main features
• Platform further solidifies Net Element’s position as a leading provider of innovative and disruptive payment solutions

Currently at the strongest financial position in its history after a highly successful 2017, global technology and value-added solutions group Net Element, Inc. (NASDAQ: NETE) is moving forward with its goal of simplifying global commerce and payments through proprietary multi-channel platform Netevia (http://nnw.fm/4xOGd).

Launched earlier this year, Netevia is a future-ready multi-channel platform designed to serve as blueprint and set of tools for global commerce and monetization by simplifying and connecting payment across different sales channels via a single integration point. Offering end-to-end payment processing services through easy APIs, the platform was designed by developers with developers in mind, according to Net Element Chief Technology Officer Andrey Krotov, and includes SDKs and sandbox for testing, offering all the building blocks and features needed to integrate payment acceptance into virtually any e-commerce solution.

Netevia is fully integrated with all major platforms, allowing vendors to accept a wide range of payment methods in multiple currencies on any device. The platform is highly flexible, being continuously adjusted and expanded so as to enable the addition of new features and services as payment needs change. Recent or still in development features include free processing in exchange for data, integration with smart terminals for card present sales, gift card solutions to drive increased sales and repeat business and, last but not least, cryptocurrency payment processing for multi-channel transactions.

In addition to flexibility and vast platform compatibility, Netevia offers merchants multiple valuable features, including instant onboarding, same day settlement and funding and payment conversion optimization that can help vendors reach 99.2 percent conversion rates and higher revenues – everything available for a highly competitive price. The latest service, added to the platform in early April 2018, was Fast Pass Funding, which allows eligible merchants to receive funding in as little as three hours during business days, a massive improvement to the previous 12- to 24- hour waiting period. Netevia also provides state-of-the-art security and fraud prevention services via more than 150 risk monitoring filters, vaulting, tokenization and point-to-point encryption.

With a focus on supporting electronic payments acceptance in a multi-channel environment, including point-of-sale, e-commerce and mobile devices, Net Element is uniquely positioned to disrupt the payment processing industry. The group is currently in its best financial situation in history, after a successful year 2017 marked by an increase in revenues ($60.1 million from $54.3 million in 2016), an improved balance sheet of $11.3 million cash in hand and financial debt of $7 million at the end of the year, and a wide array of partnerships geared toward simplifying payments across multiple sales channels worldwide.

Net Element will continue to embrace and develop innovative payment processing technologies in its efforts to capitalize on the fast-growing e-commerce market, which is expected to more than double its value over the next three years and reach $4.88 trillion by 2021, from $2.3 trillion in 2017 (http://nnw.fm/A3xNh).

For more information, visit the company’s website at www.NetElement.com

More from NetworkNewsWire

• SmartCash’s Remarkable Design Ensures Top Talent, Ongoing Innovation and International Growth
• Lithium Chile Inc. (TSX.V: LITH) (OTC: LTMCF) is “One to Watch”
• Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) Sets May Target Date for Commissioning of Asphalt Ridge Heavy Oil Extraction Facility

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$CIIX Cryptocurrency Trading Courses via Bitcoin Trading Academy, Starting June 9

SAN GABRIEL, California, April 30, 2018 /PRNewswire/ —

ChineseInvestors.com Inc. (OTCQB: CIIX)(“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, today announces new cryptocurrency and trading courses offered through its newly established Bitcoin Trading Academy LLC beginning in June 2018.

The Bitcoin Trading Academy‘s course offering will include:

Bitcoin Trading 101: Students will gain basic knowledge about Bitcoin including how to open trading accounts on the most commonly held cryptocurrency trading platforms how to set up a cryptocurrency wallet. In addition, students will be educated on Bitcoin Futures trading strategies, both long and short, how to use Bitcoin Futures to properly hedge one’s Bitcoin portfolio, and how to properly use beginner-friendly trading techniques trading techniques such as Candlesticks and Moving Averages, among other key metrics that top financial analysts use in trading assets.

Bitcoin Trading 201: The second course in the program will focus on coins such as Ethereum, including coins with significant underlying technology such as EOS, XLM, ADA and NEO, and altcoin trading platforms, such as Binance and Bittrex. In addition, this course will provide instruction on how to use information such as a coin’s underlying utility, how to use current industry and sector news in combination with technical analysis in an effort to maximize returns; and how to effectively scrutinize and understand social media feeds.

Bitcoin Trading 301: Professional ICO analyst, Preston Hom, will teach students what to look for when vetting a new cryptocurrency offering, including how to read a white paper, how to analyze the professional teams and advisory boards associated with an offering, the role that technology, marketing, trends play and what pitfalls to avoid.

“We are excited to expand our cryptocurrency education platform with the launch of Bitcoin Trading Academy, a cutting-edge cryptocurrency trading education center which follows the Company’s successful November 2017 launch of newcoins168.com, a Chinese language cryptocurrency and blockchain technology news and information site. In addition to online courses, Bitcoin Trading Academy will offer live courses in New York City,” says ChineseInvestors.com, Inc. CEO Warren Wang.

Online courses will begin June 9, 2018.  Additional course information will be provided on http://www.newcoins168.com .

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online sales and direct sales of hemp-based products and other health related products.

For more information visit: ChineseInvestors.com

Visit and register https://www.newcoins168.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Subscribe and watch our video commentaries: https://www.youtube.com/channel/UCriTFjFHCvDW_LBhiIeuLlQ/featured

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom

https://www.facebook.com/Chineseinvestors.com.english

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776

Investor Relations:
Alan Klitenic
+1-214-636-2548

Corporate Communications:
NetworkNewsWire (NNW)
New York, New York
http://www.NetworkNewsWire.com
+212-418-1217 Office
Editor@NetworkNewsWire.com

$ETST Plans to Battle Opioid Addiction with Human Clinical Trials in 2019

• Centers for Disease Control and Prevention, in March 2018, estimated ‘economic burden’ of opioid misuse at $78.5 billion annually
• ETST plans to complete white paper, begin human clinical trials by 2019; company intends to investigate drugs that combine mineral element and cannabinoid industrial hemp oil
• Goal for biotech company is to fight opioid addiction with over-the-counter (OTC) treatment drug and a cannabinoid companion generic drug

Earth Science Tech, Inc. (OTC: ETST) is planning to fight opioid addiction in the near future by completing its white paper and beginning human clinical trials in 2019. The epidemic is projected to claim nearly 500,000 American lives by 2027, according to a study by STAT (http://nnw.fm/9Twid).

The ETST white paper and planned human clinical studies deal with the measure of the efficacy of combination drugs against opioid dependency. The company will investigate the synergies between mineral elements and full spectrum cannabinoid industrial hemp with the goal of developing OTC and generic drugs that treat opioid addiction.

ETST is a biotech company focused on the cannabinoid, pharmaceutical and nutraceutical markets. In addition to drug research, it also performs R&D testing for medical devices. The company holds several subsidiaries, including Earth Science Pharmaceutical, Inc.; Cannabis Therapeutics, Inc.; KannaBidioiD, Inc.; and Canna Inno Laboratories, Inc., based in Montreal, Canada.

The company’s proposed OTC drug would be intended to reduce the cravings of opioid addicts. The other would be a generic designed to reduce the danger of side effects and make the first drug more effective, according to ETST. The purpose of the human trial is to develop a methodology that prevents fatal overdoses and relieves the side effects of withdrawal.

The Centers for Disease Control and Prevention (CDC), in a March 2018 revised report, estimated the ‘economic burden’ of opioid misuse at $78.5 billion annually in the U.S., including in that figure health care, addiction treatment and the involvement of the justice system. The National Institute on Drug Abuse terms it a national health crisis (http://nnw.fm/se3kA).

For more information, visit the company’s website at www.EarthScienceTech.com

More from NetworkNewsWire

• Uneeqo Inc. (UNEQ) is “One to Watch”
• ChineseInvestors.com, Inc. (CIIX) Eyes Chinese Expansion with Establishment of Shanghai-Based Subsidiary
• EVIO, Inc. (EVIO) Revenues Projected to Reach $10 Million in FY2019 Following Debut of EVIO Canada Subsidiary

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$NETE Sees Rising Organic Growth

• Revenues increased 11 percent during 2017, reaching $60.1 million on organic growth across all categories
• Point of sale market expected to reach $106 billion by 2025
• Global retail e-commerce sales to post solid gains, rising by more than 23 percent to $2.3 trillion by end of 2017 and accounting for 10 percent of total retail sales
• Net Element processed $2.8 billion in global transactions in 2017, a 14 percent increase
• Fast Pass Funding service unveiled on proprietary Netevia platform

Net Element, Inc. (NASDAQ: NETE), a global technology and value-added solutions group focused on supporting electronic payments acceptance in a multichannel environment, continues to master the art of the transaction by delivering valuable payment solutions to merchants and consumers.

E-commerce continues to show a healthy growth pattern, as consumers are increasingly dedicated to using their mobile devices to make purchases. According to a report compiled by Accenture Consulting (http://nnw.fm/4jY5q), consumer awareness of mobile payments is at an all-time high and first movers that deliver additional value to merchants and their customers will become the industry’s ‘game changers’.

Net Element’s new service, Fast Pass Funding, provided through the company’s proprietary Netevia platform (http://nnw.fm/jAfq4), is just one of the company’s innovative value-added services offered to merchants who are tired of waiting for funding to be processed. Eligible merchants receive funds in as little as three hours during regular business days, avoiding the 12 to 24 hour wait-time they normally endure. Other value-added services offered through the Netevia platform include fast, easy merchant account opening and integration, payment conversion optimization, over 150 risk-monitoring filters and highly competitive pricing for payment acceptance services.

People around the world are expected to make 726 billion transactions using digital payment technologies by 2020, according to an article published by CNBC (http://nnw.fm/Wa9uq). Based on analysis of payment trends during the years 2014 and 2015, the study – conducted by global consulting firm Capgemini – reported that debit cards accounted for the highest share of non-cash payments at 46.7 percent, while credit cards trailed behind at 19.5 percent. Non-cash transactions between 2014 and 2015 rose 11.2 percent, the highest growth of the past decade.

Net Element intends to capitalize on the mobile transaction market as it transforms to meet demands by consumers and merchants who pivot to embrace smart technology trends. The company’s key goals include continuing company growth in all key segments, driving client retention, expanding the company’s client base in particular markets, delivering value-added products to increase efficiencies and payment acceptance, continuing the development of Netevia and launching new tools to reach clients and deepen partner relations.

“We are very pleased with our 2017 progress and the strong balance sheet position as of December 31, 2017, which we believe positions the company for future growth and opportunities,” Firer said in a news release describing the company’s year in review and plans for 2018 (http://nnw.fm/oJS8A).

For more information, visit the company’s website at www.NetElement.com

More from NetworkNewsWire

• Uneeqo Inc. (UNEQ) is “One to Watch”
• ChineseInvestors.com, Inc. (CIIX) Eyes Chinese Expansion with Establishment of Shanghai-Based Subsidiary
• Earth Science Tech, Inc. (ETST) Plans to Battle Opioid Addiction with Human Clinical Trials in 2019

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$CIIX Eyes Chinese Expansion with Establishment of Shanghai-Based Subsidiary

• Announces expansion of cryptocurrency and blockchain education business into China
• Set to provide 24/7 coverage of the latest developments in global cryptocurrency and blockchain industry
• Launching Bitcoin Trading Academy to grow subscribers

ChineseInvestors.com, Inc. (OTCQB: CIIX) recently announced its expansion into China through the establishment of NewCoins168.com Digital Media Technology Ltd., located in Shanghai (http://cnw.fm/B6Grt). This wholly owned foreign enterprise is registered in the China Free Trade Zone with capital of 10 million RMB ($1.58 million). This expansion strengthens the company’s vision of becoming the premier financial information website for Chinese-speaking investors. CIIX prides itself on being an innovative company providing real-time market commentary, analysis and educational services in Chinese language character sets (traditional and simplified).

The company plans to hire 10 to 15 editors in Shanghai to work in conjunction with their United States counterparts at www.NewCoins168.com, which was established in November 2017 and is headquartered in New York City’s Trump Building. This joint effort between Shanghai and the United States editors will result in 24/7 coverage of the latest in global cryptocurrency and blockchain industry developments.

CIIX, through the NewCoins168.com platform, has established itself as a well-known cryptocurrency and blockchain technology information portal for the North American Chinese community. The addition of the Shanghai enterprise positions the company to bolster its popularity among the Chinese community worldwide.

CIIX Chief Executive Officer Warren Wang announced the company’s plans to launch a Bitcoin Trading Academy in June. It is expected to broadcast on NewCoins168.com. This academy will feature a three-level bitcoin trading course for Chinese-speaking investors in the U.S. (http://cnw.fm/Pec00). These courses will consist of trading in bitcoin futures, educational research and an explanation of ICOs. The recent announcement to spin off CIIX’s CBD-focused assets into a private company allows CIIX to remain focused on financial consulting, corporate brand building and educational services for cryptocurrency markets. CIIX’s focus has returned to its core skills as a financial service business for the Chinese-speaking community.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

• Earth Science Tech, Inc. (ETST) Plans to Battle Opioid Addiction with Human Clinical Trials in 2019
• EVIO, Inc. (EVIO) Revenues Projected to Reach $10 Million in FY2019 Following Debut of EVIO Canada Subsidiary
• Global Hemp Group, Inc. (CSE: GHG) (FRA: GHG) (OTC: GBHPF) Building Portfolio on Promise of Revitalized Hemp Industry

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$SNNVF Delivers High-quality Products and Services to Cannabis Markets

April 19, 2018

• Uniquely positioned in the largest legalized medical and recreational cannabis markets – California and Canada
• Construction underway for a modern, agri-technology greenhouse facility in California capable of producing over 100,000 kg of premium medical cannabis annually, once phase 1 and 2 are complete
• Received all required California temporary licenses to cultivate, process cannabis; will apply for annual state licenses within next four months
• Designs completed for purpose-built current Good Manufacturing Practice (cGMP) compliant greenhouse facilities in British Columbia capable of producing 100,000 kg of premium medical cannabis per year and over 25,000 kg of trim used for extraction
• Application for medical cannabis production license at BC facility from Health Canada under final review

Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – committed to delivering safe, consistent, high-quality products and services. Sunniva operates through its wholly owned subsidiaries: Sunniva Medical Inc., CP Logistics, LLC, Natural Health Service Ltd., and Full-Scale Distributors, LLC. Sunniva’s vision is to become the lowest cost, highest quality cannabis producer in the markets it serves by building large scale purpose-built cGMP compliant greenhouses, offering best quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education, and sourcing better therapeutic delivery devices.

The company is establishing sophisticated distribution channels, including Sunniva’s ownership of Natural Health Services Ltd. cannabis clinics in Canada with over 95,000 active patients, to purchase the significant quantities of high quality Sunniva-branded and Sunniva private-labeled cannabis products.

Sunniva is an ancient English name which means, “Gift of the Sun.” Sunniva’s team of horticulturists, scientists and engineers is helping to set best practices for the industry, believing that sun-grown, solar-powered cultivation is the most sustainable and cost-effective way to grow high-quality, premium cannabis.

The Sunniva Family includes:

CP Logistics, LLC

Through its subsidiary, CP Logistics LLC, Sunniva is developing the Sunniva Campus, a state-of-the-art, purpose-built greenhouse facility in Cathedral City, California. This modern purpose-built, agri-technology greenhouse is designed to be cGMP compliant which assures proper design, monitoring and control of manufacturing processes and facilities.

Phase 1 of the project includes a fully funded 325,000 square foot greenhouse capable of producing 60,000 kg per year of dry cannabis at capacity with operations commencing Q3 2018. Approximately 50 percent of initial total production will be converted into oils and extracts. Phase 2 is expected to increase the greenhouse by 165,000 square feet and grow production by about 40,000 kgs. per year.

These uniquely sealed greenhouses are designed to deploy custom, automation assembly line cultivation processes at a large scale. Energy consumption will be reduced while utilizing the energy of the sun and microclimatic controls to provide precise growing conditions. The greenhouse will recirculate air for more efficient climate control, and the company’s Integrated Pest Management System is designed to ensure every plant grown is certified clean and free of all contaminants and pesticides.

Sunniva Medical Inc.

Sunniva Medical Inc. is designing and preparing to break ground on the Sunniva Canada Campus encompassing 700,000 square feet of purpose-built cGMP greenhouse facilities in the Okanagan Valley, British Columbia. The total campus is expected to produce 100,000 kg of premium medical cannabis annually plus additional trim used for extraction. This facility will produce pesticide-free products and will convert trim to extracted products such as cannabis oil that can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams.

Sunniva and Canopy Growth Corporation (Canopy Growth) recently announced a large take or pay supply agreement. Under the terms of the agreement, Canopy Growth will purchase up to 45,000 kgs. of dried cannabis annually commencing Q1 2019, which includes the distribution of Sunniva branded products. Sunniva Medical is a late-stage applicant under Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) and is in the final review stage of the process.

Natural Health Services Ltd.

Natural Health Services Ltd. owns and operates a network of eight medical clinics in Canada specializing in medical cannabis under the ACMPR. Natural Health Services connects licensed producers to their 21 physicians and patients with its proprietary SPARK software which utilizes a software-as-a-service revenue model. To date, there are 27 integrated licensed producers utilizing the SPARK software.

In-house physicians specializing in the endocannabinoid system provide expert consultation, education and recommendations for targeted phytoceutical remedies and wellness plans to improve the quality of life for all patients. NHS enjoys a long-term relationship with patients due to the quality of its physician-patient experience. A rapidly expanding NHS cannabis clinic network serves 94,000 active patients in Canada. NHS has also initiated a pilot program with a national pharmacy chain to aggregate more patients.

Full-Scale Distributors, LLC

Full-Scale Distributors, LLC is an industry leading provider of custom, private-label vaporizers through its brand, Vapor Connoisseur. The company currently serves the needs of over 80 top brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative therapeutic delivery devices. Products are tailored to client needs, ensuring both safety and reliability.

Sunniva’s highly experienced management team is building partnerships with leading scientists, universities and clinical trial groups to deliver proprietary cannabis formulations to a broad spectrum of health ailments and conditions. These global partners require cGMP-certified facilities for the processing and manufacturing of cannabis products. Sunniva is committed to providing safe, pesticide-free, high quality, reproducible cannabis medicines.

Leading Sunniva is co-founder, chairman and CEO Dr. Anthony (Tony) Holler. He is the former CEO and founder of ID Biomedical, which was acquired in 2005 for $1.7 billion by GlaxoSmithKline. He is also the former chairman of Corriente Resources Inc., which was sold for approximately $700 million to CRCC-Tongguan Investment Co. Dr. Holler is currently chairman of CRH Medical Corporation, a public company trading on the TSX and NYSE. His expertise includes strategic planning, mergers and acquisitions and financing with a singular focus on increasing shareholder value.

Dr. Holler is joined by co-founder Leith Pedersen, who serves as president of Sunniva. Pedersen is the former owner and CEO of Vida Wealth Management Bahamas and was a former investment advisor at Canaccord Wealth Management. He is a former partner and director at JF Mackie and Company, an independent brokerage firm in Calgary, Alberta, that managed capital in excess of $2 billion for high net worth clients. Pedersen’s expertise is in corporate strategy, financing and mergers and acquisitions.

For more information, visit the company’s website at www.sunniva.com

More from CannabisNewsWire

• ChineseInvestors.com, Inc. (CIIX) Eyes Chinese Expansion with Establishment of Shanghai-Based Subsidiary
• Earth Science Tech, Inc. (ETST) Plans to Battle Opioid Addiction with Human Clinical Trials in 2019
• EVIO, Inc. (EVIO) Revenues Projected to Reach $10 Million in FY2019 Following Debut of EVIO Canada Subsidiary

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net